ALLEGATO B

UNIVERSITÀ DEGLI STUDI DI MILANO
selezione pubblica per n.___ posto/i di Ricercatore a tempo determinato ai sensi dell'art.24, comma 3, lettera a) della Legge 240/2010 per il settore concorsuale _____: 06/N1 - Scienze delle Professioni Sanitarie e delle Tecnologie Mediche Applicate_____ , **settore scientifico-disciplinare _____**MED/50 - Scienze Tecniche Mediche Applicate____ **presso il Dipartimento di ___**SCIENZE BIOMEDICHE, CHIRURGICHE E ODONTOIATRICHE, **(avviso bando pubblicato sulla G.U. n. __3_____ del _13-01-23_____) Codice concorso __5182__**

Chiara Fenoglio
CURRICULUM VITAE

(N.B. IL CURRICULUM NON DEVE ECCEDERE LE 30 PAGINE E DEVE CONTENERE GLI ELEMENTI CHE IL CANDIDATO RITIENE UTILI AI FINI DELLA VALUTAZIONE.
LE VOCI INSERITE NEL FACSIMILE SONO A TITOLO PURAMENTE ESEMPLIFICATIVO E POSSONO ESSERE SOSTITUITE, MODIFICATE O INTEGRATE)

INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)

COGNOME	**FENOGLIO**
NOME	**CHIARA**
DATA DI NASCITA	01-05-1975

TITOLI

TITOLO DI STUDIO
(indicare la Laurea conseguita inserendo titolo, Ateneo, data di conseguimento, ecc.)

Scienze Biologiche conseguita presso l'Università degli Studi di Milano il 25-07-2001

TITOLO DI DOTTORE DI RICERCA O EQUIVALENTI, OVVERO, PER I SETTORI INTERESSATI, DEL DIPLOMA DI SPECIALIZZAZIONE MEDICA O EQUIVALENTE, CONSEGUITO IN ITALIA O ALL'ESTERO
(inserire titolo, ente, data di conseguimento, ecc.)

Dottorato di ricerca in Scienze Neurologiche e del Dolore conseguito presso l'università degli studi di Milano il 29-11-2005

CONTRATTI DI RICERCA, ASSEGNI DI RICERCA O EQUIVALENTI
(per ciascun contratto stipulato, inserire università/ente, data di inizio e fine, ecc.)

2008-2012 Assegno di ricerca di tipo A (2+2 anni, concorso per titoli e colloquio) sul tema "Analisi genetica e funzionale del cromosoma 17 nella malattia di Alzheimer: cluster delle chemochine e progranulina"

2012-2013 Assegno di ricerca di tipo B sul tema "Determinazione contemporanea di metaboliti per la diagnostica delle demenze ed in particolare della malattia di Alzheimer"

2013-2014 Ruolo dei micro(mi)RNA nella malattia di Alzheimer (AD) e demenze correlate: nuovi possibili scenari per la comprensione del meccanismo patogenetico e la scoperta di biomarcatori precoci

2015-2017 Assegno di ricerca di tipo B sul tema "Determinazione contemporanea di metaboliti per la diagnostica delle demenze ed in particolare della malattia di Alzheimer.

2017-2019 assunzione a tempo determinato presso l'Università di Milano, Dipartimento di Fisiopatologia e dei Trapianti, in qualità di tecnico laureato Cat D

2019- ad oggi assunzione a tempo indeterminato presso l'Università di Milano, Dipartimento di Fisiopatologia e dei Trapianti, in qualità di tecnico laureato Cat D

ATTIVITÀ DIDATTICA A LIVELLO UNIVERSITARIO IN ITALIA O ALL'ESTERO
(inserire anno accademico, ateneo, corso laurea, numero ore, ecc.)

A.A. 2011-2012 corso elettivo facoltà medicina e chirurgia : Genetica Molecolare Della malattia di Alzheimer. D-E1C3 Università degli Studi di Milano, 3 ore di lezione dal titolo: Demenza di Alzheimer e Frontotemporale: fattori di rischio genetici.

Da A.A. 2012-2013 a A.A. 2022-2023, scuola di specializzazione in Farmacia Ospedaliera/corso integrato terapie delle malattie del SNC/ S.S.D MED/03 (1(CFU) modulo: Basi genetiche delle malattie neurodegenerative Università degli Studi di Milano, 2 ore di lezione dal titolo: Epidemia, patogenesi, genetica della Sclerosi Multipla.

A.A. 2014-2015 Corso elettivo facoltà medicina e chirurgia: Biochimica Fisiologica e Patologica della neurotrasmissione. D-E33H, Università Degli Studi di Milano, 6 ore. Titolo: Genetica Molecolare Della malattia di Alzheimer

A.A. 2015-2016, Dottorato di Medicina Molecolare e Traslazionale dell'Università degli Studi di Milano, corso "Acquisizione di conoscenze su MND: eziopatogenesi e terapia molecolare, modelli" (12 ore) 2CFU, lezione di 2 ore dal titolo: "Ruolo dei non coding RNA esosomiali nelle patologie Neurodegenerative "

A.A. 2016-2017, Dottorato di Medicina Molecolare e Traslazionale dell'Università degli Studi di Milano, corso "Acquisizione di conoscenze su MND: eziopatogenesi e terapia molecolare, modelli" (12 ore) 2CFU, lezione di 2 ore dal titolo: "Gli esosomi nella comunicazione intercellulare: ruolo nelle malattie neurodegenerative"

A.A. 2017-2018, Dottorato di Medicina Molecolare e Traslazionale dell'Università degli Studi di Milano, corso "Aspetti clinico/molecolari e di prospettiva terapeutica nelle malattie neurodegenerative (MND)" (12 ore) 2CFU, lezione di 2 ore dal titolo: "Gli esosomi nella comunicazione intercellulare: ruolo nelle malattie neurodegenerative"

DOCUMENTATA ATTIVITÀ DI FORMAZIONE O DI RICERCA PRESSO QUALIFICATI ISTITUTI ITALIANI O STRANIERI;
(inserire anno accademico, ente, corso, periodo, ecc.)

A.A. 2001-2002 Borsa di ricerca annuale (per titoli e colloquio) del Centro di Eccellenza sulle Patologie Neurodegenerative sul tema "Parametri neuroendocrinologici nella malattia di Alzheimer: utilità clinica come marcatori biologici per la diagnosi precoce e differenziale" svolta presso la clinica neurologica dell'Ospedale Maggiore Policlinico.

A.A. 2002-2005 Titolare di borsa di studio triennale per lo svolgimento del Dottorato di Ricerca in Scienze Neurologiche e del Dolore presso il Dipartimento di Scienze Neurologiche dell'Università di Milano, IRCCS Ospedale Maggiore, Milano.

A.A. 2004-2005 Vincitrice di un fellowship finanziato dalla Società Europea di Neurologia (European Neurological Society, ENS) sul progetto dal titolo: Role of polymorphisms in genes coding for adhesion molecules in Multiple Sclerosis svolto presso il dipartimento di Neuroscienze Cliniche dell'Università di Cambridge, UK. Supervisori: Prof. DAS Compston, Dr. S. Sawcer.

A.A. 2005-2006 Borsa di ricerca (concorso per titoli e colloquio) sul tema:" Studio multidisciplinare in alcune malattie neurodegenerative con demenza: diagnosi precoce ed evoluzione clinica, neuroimaging, trattamenti terapeutici farmacologici e validazione di percorsi riabilitativi motori cognitivi, ricerche eziopatogenetiche biologico-molecolari nell'uomo e in modelli animali", bandita dall'Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena di Milano, svolta presso il Dipartimento di Scienze Neurologiche, Ospedale Maggiore, Milano.

A.A. 2006-2007 Borsa di ricerca (concorso per titoli e colloquio) sul tema "Reclutamento leucocitario nel Sistema Nervoso Centrale: identificazione di nuovi bersagli farmacologici nelle malattie infiammatorie cerebrali" bandita dall'Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena di Milano, svolta presso il Dipartimento di Scienze Neurologiche, Ospedale Maggiore, Milano.

A.A.2007-2008 Borsa di ricerca (concorso per titoli e colloquio) sul tema "Meccanismi infiammatori alla base della conversione del Mild Cognitive Impairment in demenza di Alzheimer" bandita dall'Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena di Milano, svolta presso il Dipartimento di Scienze Neurologiche, Ospedale Maggiore, Milano.

REALIZZAZIONE DI ATTIVITÀ PROGETTUALE
(indicare, data, progetto, ecc.)

Anno 2008: Analisi genetica e funzionale di loci candidati per la malattia di Alzheimer: possibile identificazione di nuovi target terapeutici. Ricerca a Concorso dell'IRCCS Fondazione Cà Granda Ospedale Policlinico. Ruolo nel progetto: Responsabile scientifico, durata: 24 mesi. FINANZIATO

Anno 2009: Gene expression, RNA silencing and proteomics longitudinal analysis in patients with Multiple Sclerosis: identification of new tools to predict therapy response. Progetto giovani ricercatori del ministero della Salute. Ruolo nel progetto:responsabile scientifico.

Anno 2009: Identification of genetic factors involved in primary progressive multiple sclerosis: a model of neuro-degeneration. Progetto giovani ricercatori del Ministero della Salute: Ruolo nel progetto: collaboratore, durata 36 mesi. FINANZIATO

Anno 2010: Exploring immune gene regulation by microRNAs in multiple sclerosis: from candidate to modifier genes. Progetto giovani ricercatori del Ministero della Salute. Ruolo nel Progetto: responsabile scientifico.

Anno 2011: Genetic and functional analysis of dysregulated human and viral miRNAs in patients with multiple sclerosis as potential biomarkers of clinical prognosis and therapeutic response. Progetto ERC-2012-starting grant. Ruolo nel progetto: responsabile scientifico.

Anno 2011: The GENetic Frontotemporal Dementia Initiative (GENFI): a new multi-centre platform (Progetto Europeo), ruolo nel progetto: genetic guardian, durata 24 mesi, approvato dal CE

Anno 2012: Joint Program on Neurodegenerative Diseases (Progetto Europeo), ruolo nel progetto: collaboratore, durata del progetto 36 mesi, approvato dal CE

Anno 2012:ANACONDA: consorzio italiano sulle demenze neurodegenerative. Ruolo nel progetto: collaboratore

Anno 2013: Identifying Multiple Sclerosis causal mechanisms and biomarkers by combined analysis of genotype, protein profiles, miRNA data in multiplex families and unrelated individuals. Progetto presentato alla Fondazione CARIPLO presentato in collaborazione con Università di Pavia. Ruolo nel progetto: responsabile scientifico di unità operativa.

Anno 2013: Optimization of plasma progranulin dosage for predicting null progranulin mutations in neurodegenerative diseases: A pilot Multicentre Italian Study for harmonization of procedures to be translated into clinical practice. Progetto presentato come Ricerca Finalizzata del Ministero della Salute. Ruolo nel progetto: responsabile scientifico di unità operativa.

Anno 2013: Autosomal dominant Frontotemporal Lobar Degeneration: epigenetics and inflammatory factors as new tools for understanding disease mechanisms and biomarker discovery. Progetto presentato alla Fondazione Cariplo. Ruolo nel progetto: resposabile scientifico.

Anno 2013: Studio dello sbilanciamento tra cellule T patogeniche e regolatorie nei pazienti con sclerosi multipla come predittore della progressione della malattia e della risposta alla terapia. Progetto presentato a FISM da INGM. Ruolo nel progetto: collaboratore

Anno 2014: Autosomal Dominant and sporadic Frontotemporal Lobar Degeneration: from non-coding RNAs to the identification of preclinical biomarkers and therapeutic targets. . Progetto presentato come Ricerca Giovani Ricercatori del Ministero della Salute. Ruolo nel progetto: responsabile scientifico di unità operativa

Anno 2014: Autosomal Dominant and sporadic Frontotemporal Lobar Degeneration: from non-coding RNAs to clinical biomarkers discovery. Progetto presentato alla Fondazione CARIPLO. Ruolo nel progetto: responsabile scientifico

Anno 2015: Long non coding (LncRNAs) expression analysis in patients with MS: potential biomarkers of disease susceptibility and progression. Progetto presentato a FISM. Ruolo nel progetto: responsabile scientifico.

Anno 2015: Long non coding (Lnc)RNAs expression analysis in patients with multiple sclerosis: potential biomarkers of disease and progression. Progetto vincitore del bando “curiosity driven” dell’Università degli Studi di Milano. 10.000 euro

Anno 2016: Non coding RNAs in neurally derived blood exosomes in Multiple Sclerosis: identification of potential biomarkers of disease and progression. Progetto presentato a Merck/Serono nell’ambito del Grant for Multiple Sclerosis innovation. Ruolo nel progetto: responsabile scientifico.

ORGANIZZAZIONE, DIREZIONE E COORDINAMENTO DI GRUPPI DI RICERCA NAZIONALI E INTERNAZIONALI, O PARTECIPAZIONE AGLI STESSI
(per ciascuna voce inserire anno, ruolo, gruppo di ricerca, ecc.)

2006-2008 Coordinamento e supervisione di 1 studente, 1 dottorando in medicina molecolare, 1 dottorando in patologia e neuropatologia sperimentali Dipartimento di Scienze Neurologiche Università delgi Studi, Milano

2008-2010 Coordinamento e supervisione di 2 studenti, 2 dottorandi in medicina molecolare Dipartimento di Scienze Neurologiche Università delgi Studi, Milano

2010-2012 Coordinamento e supervisione di 1 tecnico ospedaliero, 2 dottorandi in medicina molecolare, 2 studenti Dipartimento di Scienze Neurologiche Università degli Studi, Milano

2012-2017 Coordinamento e supervisione di 1 tecnico ospedaliero, 1 borsista neolauretato, 1 borsista postdoc, 1 assegnista di ricerca tipo A, 1 dottorando in medicina molecolare Dipartimento di Fisiopatologia Medico Chirurgica e dei Trapianti, Università degli Studi di Milano.

2017- 2023 1 borsista neolauretato, 1 borsista postdoc, 1 assegnista di ricerca tipo B, 1 dottorando in medicina molecolare e traslazionale, tesisti in laurea triennale di Biotecnologia presso l'Università degli Studi di Milano e Tesisti del cosro di Laurea magistrale del corsi di Neuroscienze presso l'università degli Studi di Pavia e Biotecnolgie Mediche.

Membro della rete RIN del MoH (Rete delle Neuroscienze e della Riabilitazione).

Genetic Guardian del consorzio GEnetic Iniziative Frontotemporal Dementla- GENFI,coordinatore Jon Rohrer (UCL, London).

Membro del consorzio Diagnostic and Prognostic Precision medicine for behavioral variant Frontotemporal Dementia, (DIPPA-FTD) coordinatore Prof. Yolande Pijnenburg.

Membro del consorzio PROgnostic GEnetic factors in MUltiple Sclerosis (PROGEMUS) coordinatori Prof. D'Alfonso, Dr Leone.

Membro del consorzio Neuropsychiatric International Consortium on Frontotemporal Dementia -NIC FTD.

Membro del consorzio internazionale EADB Alzheimer's disease European biobank e IGAP- International Genomics of Alzheimer's Project. (coordinatore Dr. Philippe Lambert)

Membro di International FTD-Genomic consortium (coordinatore Raffaele Ferrari)

ATTIVITÀ DI RELATORE A CONGRESSI E CONVEGNI NAZIONALI E INTERNAZIONALI
(inserire titolo congresso/convegno, data, ecc.)

Invio di 300 abstract a congressi nazionali e internazionali di cui le seguenti comunicazioni orali o letture su invito:

17-19/10/2002 XIII Meeting of the Italian Association of Neuroimmunology (AINI) Moltrasio10-12/06/2003 XXXIX Annual Meeting of the italian Neuropathological association Siena.

14-18/06/2003 XIII Meeting of the European Neurological Society, Istanbul, Turkey

17-20/09/2003 19th Congress of the European Committee for Treatment and Research in multiple Sclerosis (ECTRIMS) Milan, Italy.

22-25/10/2003 XVI Meeting of the Italian Association of Neuroimmunology (AINI) Taormina

26-30/06/2004 XIV Meeting of the European Neurological Society Barcelona, Spain.

28/09-02/10/2004 7th International Congress of Neuroimmunology Venice , Italy.

18-22/06/2005 XV Meeting of the European Neurological Society, Vienna, Austria.

27-31/05/2006 XVI Meeting of the European Neurological Society Lausanne,Switzerland.

15-20/07/2006 X International Conference on Alzheimer's disease and related disorders. Madrid, Spain.

30/9-3/10 43rd Annual Meeting of the Italian Association of Neuropathology (AINP) – XXXIII Meeting of the Italian Association for Resesrch on Brain Aging. Verona, Italy.

27/04/2007Meeting ANBI (Associazione Nazionale Biotecnologi Italiani), intervento dal titolo: discriminazione allelica per la genotipizzazione di SNPs nel gDNA: applicazione in studi genetici di associazione. Milano

11-14/10/2007 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Prague, Czech Republic.

7-11/06/2008 XVIII Meeting of the European Neurological Society. Nice, France.

18-21/06/2008 XLIV Annual Meeting of the Italian Association of Neuropathology (AINP) – XXXIV Meeting of the Italian Association for Resesrch on Brain Aging (AIRIC). Milan, Italy.

26-31/07/2008 Alzheimer's Association International Conference on Alzheimer's disease. Chicago, IL, USA

20-24/06/2009 XIX Meeting of the European Neurological Society. Milan, Italy.

9-12/09/2009 25rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Dusseldorf, Germany.

18-20/03/2010. V SINdem meeting.Florence, Italy

17-19/03/2010 VI SINdem meeting, March 17-19. Milan, Italy

19-22/10/ 2011 5th Joint Triennal Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS). Amsterdam, The Netherlands.

22-24/02/2011 VII SINdem meeting, March 22-24. Naples, Italy

24-26/05/2012 XLVIII Annual Meeting of the Italian Association of Neuropathology (AINP) – XXXVIII Meeting of the Italian Association for Research on Brain Aging (AIRIC). Naples, Italy.

10-13/10/2012 16th Joint Triennal Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS). Lyon, France.

30/05-01/06/2013 39° Meeting of the Italian Association for Research on Brain Aging (AIRIC). Pisa, Italy

23-25/05/2013 Top Seminars in Multiple Sclerosis: MicroRNAs in MS: role in the pathogenesis and potential use as biomarker. Baveno

26-28/05/2016 42° congresso AIRIC Associazione italiana Ricerca Invecchiamento Cerebrale, Roma Non coding RNAs (LncRNAs) in neurodegenerative diseases: from the identification of preclinical biomarkers toward the discovery of therapeutic targets

01-04/10/2017 congresso italiano di Neuroscienze, Ischia. Non coding RNAs in Alzheimer's Disease and related dementia: from the identification of preclinical biomarkers toward the discovery of therapeutic targets.

06/07/2018 congresso su *IL METABOLISMO DELL'RNA NELLE MALATTIE NEUROLOGICHE:Apporto degli RNA non codificanti alla regolazione genica, IRCCS Mondino Pavia. microRNAs nella malattia di Alzheimer e nelle demenze correlate*

19-21/04/2018 XIII convegno nazionale SINDEM, Firenze Tecniche NGS: WES e WGS per l'identificazione di geni causali. Implicazioni in ambito diagnostico-differenziale

23-25/05/2019 45°congresso AIRIC, Bologna. Detection of rare variants in patients affected by neurodegenerative diseases using Haloplex^{HS} target enrichment system.

02-05/11/2022 ISTFTD meeting, Lille-Paris.PERIPHERAL INFLAMMATORY PROFILE IN PATIENTS WITH GENETIC FRONTOTEMPORAL DEMENTIA.

CONSEGUIMENTO DI PREMI E RICONOSCIMENTI NAZIONALI E INTERNAZIONALI PER ATTIVITÀ DI RICERCA
(inserire premio, data, ente organizzatore, ecc.)

Vincitrice di un fellowship finanziato dalla Società Europea di Neurologia (European Neurological Society, ENS) sul progetto dal titolo: Role of polymorphisms in genes coding for adhesion molecules in Multiple Sclerosis svolto presso il dipartimento di Neuroscienze Cliniche dell'Università di Cambridge, UK. Supervisori: Prof. DAS Compston, Dr. S. Sawcer

PRODUZIONE SCIENTIFICA

PUBBLICAZIONI SCIENTIFICHE
(per ciascuna pubblicazione indicare: nomi degli autori, titolo completo, casa editrice, data e luogo di pubblicazione, codice ISBN, ISSN, DOI o altro equivalente)

Pubblicazione su volumi:

Galimberti D, Fenoglio C, Scarpini E. Immunological Aspects in Neurodegenerative Disorders. In: "Neuroimmunology Research Focus" 2007: 5-42. Novapublishers, New York, USA (Editor: Paulo V. Broglio).

Galimberti D, Fenoglio C, Scarpini E. Early onset dementia: role of genetics in the pathogenesis of Alzheimer's disease and Frontotemporal Lobar Degeneration. In: "Alzheimer Disease in the Middle-Aged" 2008: 329-245. Novapublishers, New York, USA (Editor: Hyun Sil Jeong)

Galimberti D, Fenoglio C, Scarpini E. Alzheimer's disease: from pathogenesis to new perspectives for treatment. In: "A Multidisciplinary Approach to Dissect the Alzheimer's Pathology" 2008: 111-129. Transworld Research Network, 37/661 (2), Fort P.O., Trivandrum-695 023, Kerala, India (Editors: Roberto Dominici and Ida Biunno)

Galimberti D, Fenoglio C, Scarpini E. Novel Therapies for Alzheimer's Disease: Potentially Disease Modifying Drugs. In: "Cognitive Impairment: causes, diagnosis and treatments", 2009, Novapublishers, New York, USA (Editor: Melanie L. Landow).

Fenoglio C, Scarpini E, Galimberti D. Gender-related genetic and biochemical differences: influence on susceptibility and course of multiple sclerosis. In: "Women and Multiple Sclerosis" 2009, Novapublishers, New York, USA (Editor: Duane O'Mahoni and Anrai de Burca).

Galimberti D, Fenoglio C, Scarpini E. Genetics and Molecular Biology of Alzheimer's disease and Frontotemporal Lobar Degeneration: analogies and differences. In: "Neurodegeneration: theory, disorders and treatment" 2011: 173-88. Novapublisher, New York, USA (Editor: Alexander S. McNeill).

Galimberti D, Fenoglio C, Scarpini E. Novel therapies for Alzheimer's disease: potentially disease modifying drugs. In: "Alzheimer's disease research compendium" 2013: 73-96. Novapublishers, New York, USA (Editor: Miao-Kun Sun).

ARTICOLI SU RIVISTE

1. Fenoglio C, Galimberti D, Lovati C, Guidi I, Gatti A, Fogliarino S, Tiriticco M, Mariani C, Forloni G, Pettenati C, Baron PL, Conti G, Bresolin N, Scarpini E. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiology of Aging 2004; 25(9):1169-1173. doi: 10.1016/j.neurobiolaging.2003.11.008

2. Galimberti D, Fenoglio C, et al. CCR2-64I polymorphism and CCR5Δ32 deletion in patients with Alzheimer's disease. J. Neurol. Sci. 2004; 225:79-83. doi: 10.1016/j.jns.2004.07.005.

3. Guidi I, Galimberti D, Venturelli E, Lovati C, Del Bo R, Fenoglio C, et al. Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients. Neurobiology of Aging 2005; 26:789-794. doi: 10.1016/j.neurobiolaging.2004.07.003.

4. Del Bo R, Scarlato, M, Ghezzi S, Martinelli Boneschi F, Fenoglio C, et al. Vascular Endothelial Growth Factor gene variability is associated with increased risk of Alzheimer's disease. Annals of Neurology 2005; 57:373-380. doi: 10.1002/ana.20390.

5. Galimberti D, Venturelli E, Gatti A, Lovati C, Fenoglio C, Mariani C, Forloni G, Bresolin N, Scarpini E. Association of neuronal Nitric Oxide Synthase C276T polymorphism with Alzheimer's disease. Journal of Neurology 2005; 252:985-986. doi: 10.1007/s00415-005-0783-2.

6. Venturelli E, Galimberti D, Lovati C, Fenoglio C, Mariani C, Forloni G, Bresolin N, Scarpini E. The T-786C NOS3 polymorphism in Alzheimer's disease: association and influence on gene expression. Neurosci. Letters 2005; 382:300-303. doi: 10.1016/j.neulet.2005.03.032

7. Galimberti D, Fenoglio C, et al. E-selectin A561C and G98T polymorphisms influence susceptibility and progression of Multiple Sclerosis. J. Neuroimmunol. 2005;165: 201-205.

8. Scalabrini D, Galimberti D, Fenoglio C, et al. P-selectin glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with Multiple Sclerosis. Neurosci. Letters 2005; 388: 149-152.

9. Fenoglio C, Galimberti D, Ban M, Maranian M, Scalabrini D, Venturelli E, Piccio L, De Riz M, Yeo T, Goris A, Gray J, Bresolin N, Scarpini E, Compston A, Sawcer S. SELPLG and SELP single nucleotide polymorphisms in multiple sclerosis. Neurosci Lett. 2006 Feb 13;394(2):92-6. doi: 10.1016/j.neulet.2005.10.014. Epub 2005 Oct 27.

10. Galimberti D, Fenoglio C, et al. Serum MCP-1 levels are increased in Mild Cognitive Impairment and mild Alzheimer's disease. Neurobiol Aging. 2006 Dec;27(12):1763-8. doi: 10.1016/j.neurobiolaging.2005.10.007. Epub 2005 Nov 22.

11. Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, Fenoglio C, Venturelli E, Baron PL, Bresolin N, Scarpini E. Oxidative imbalance in patients with Mild Cognitive Impairment and Alzheimer's disease. Neurobiology of Aging 2006; 27:262-9. doi:10.1016/j.neurobiolaging.2005.01.001.

12. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Venturelli E, Pijnenburg YAL, Bresolin N, Scarpini E. Intrathecal chemokine levels in Alzheimer's disease and Frontotemporal Lobar degeneration. Neurology. 2006 Jan 10;66(1):146-7. doi: 10.1212/01.wnl.0000191324.08289.9d.

13. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, Guidi I, Blankenstein MA, Bresolin N, Scarpini E. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2006 Apr;63(4):538-43. doi: 10.1001/archneur.63.4.538.

14. Del Bo, Scarlato M, Ghezzi S, Martinelli-Boneschi F, Fenoglio C, et al. Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. Neurobiol Aging. 2006 May;27(5):770.e1-770.e5. doi: 10.1016/j.neurobiolaging.2005.05.025. Epub 2005 Aug 15.

15. Venturelli E, Galimberti D, Fenoglio C, et al. Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease. Neurosci Lett. 2006 Aug 14;404(1-2):217-21. doi: 10.1016/j.neulet.2006.05.054. Epub 2006 Jun 19

16. Galimberti D, Scalabrini D, Fenoglio C, et al..CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. Eur. J. Neurol. 2007;14:162-167.

17. Galimberti D, Venturelli E, Fenoglio C, Lovati C, Guidi I, Scalabrini D, Mariani C, Bresolin N, Scarpini E. IP-10 serum levels are not increased in Mild Cognitive Impairment and Alzheimer disease. Eur J Neurol. 2007 Apr;14(4):e3-4. doi: 10.1111/j.1468-1331.2006.01637.x.

18. Fenoglio C, Galimberti D, Piccio L, Scalabrini D, Panina P, Buonsanti C, Venturelli E, Lovati C, Forloni G, Mariani C, Bresolin N, Scarpini E. Absence of TREM2 polymorphisms in patients with Alzheimer's disease and Frontotemporal Lobar Degeneration. Neurosci Lett. 2007 Jan 10;411(2):133-7. doi: 10.1016/j.neulet.2006.10.029. Epub 2006 Nov 7.

19. Galimberti D, Scalabrini D, Fenoglio C, Comi C, De Riz M, Venturelli E, Lovati C, Mariani C, Monaco F, Bresolin N, Scarpini E. CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. Eur J Neurol. 2007 Feb;14(2):162-7. doi: 10.1111/j.1468-1331.2006.01629.x.

20. Yeo TW, De Jager PL, Gregory SG, Barcellos LF, Walton A, Goris A, Fenoglio C, Ban M, Taylor CJ, Goodman RS, Walsh E, Wolfish CS, Horton R, Traherne J, Beck S, Trowsdale J, Caillier SJ, Ivinson AJ, Green T, Pobywajlo S, Lander ES, Pericak-Vance MA, Haines JL, Daly MJ, Oksenberg JR, Hauser SL, Compston A, Hafler DA, Rioux JD, Sawcer S. A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol. 2007 Mar;61(3):228-36. doi: 10.1002/ana.21063.

21. Galimberti D, Scarpini E, Venturelli E, Strobel A, Herterich S, Fenoglio C, Guidi I, Scalabrini D, Cortini F, Bresolin N, Lesch KP, Reif A. Association of a NOS1 promoter repeat with Alzheimer's disease.Neurobiol Aging. 2008 Sep;29(9):1359-65. doi: 10.1016/j.neurobiolaging.2007.03.003.

22. Castelli L, Comi C, Chiocchetti A, Nicola S, Mesturini R, Giordano M, D'Alfonso S, Cerutti E, Galimberti D, Fenoglio C, Tesser F, Yagi J, Rojo JM, Perla F, Leone M, Scarpini E, Monaco F, Dianzani U. ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution. J Neuroimmunol. 2007 May;186(1-2):193-8. doi: 10.1016/j.jneuroim.2007.03.022. Epub 2007 Ma

23. Scalabrini D, Fenoglio C, Scarpini E, De Riz M, Comi C, Venturelli E, Cortini F, Piola M, Villa C, Naldi P, Monaco F, Bresolin N, Galimberti D. Candidate gene analysis of SPARCL1 gene in patients with Multiple Sclerosis, Neurosci Lett. 2007 Oct 2;425(3):173-6. doi: 10.1016/j.neulet.2007.08.020. Epub 2007 Aug 17.

24. Galimberti D, Scalabrini D, Fenoglio C, et al. Gender-specific influence of the chromosome 14 chemokine gene cluster on the susceptibility to Multiple Sclerosis. J Neurol Sci. 2008 Apr 15;267(1-2):86-90. doi: 10.1016/j.jns.2007.10.001.

25. Venturelli E, Villa C, Scarpini E, Fenoglio C, et al.Neuronal nitric oxide synthase C276T polymorphism increases the risk for frontotemporal lobar degeneration. Eur J Neurol. 2008 Jan;15(1):77-81. doi: 10.1111/j.1468-1331.2007.02007.x.

26. Galimberti D, Fenoglio C,et al. MDC/CCL22 intrathecal levels in patients with multiple sclerosis. Mult Scler. 2008 May;14(4):547-9. doi: 10.1177/1352458507084268.

27. Galimberti D, Venturelli E, Fenoglio C, et al. Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. J Neurol. 2008 Apr;255(4):539-44. doi: 10.1007/s00415-008-0737-6.

28. Reif A, Scarpini E, Venturelli E, Töpner T, Fenoglio C, Lesch KP, Galimberti D.The functional MAOA-uVNTR promoter polymorphism in patients with frontotemporal dementia. Eur J Neurol. 2008 Jun;15(6):637-9. doi: 10.1111/j.1468-1331.2008.02142.x.

29. Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, Galimberti D, Scarpini E, Morris JC, Fagan AM, Holtzman DM, Goate AM.Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8050-4. doi: 10.1073/pnas.0801227105.

30. Benerini Gatta L, Vitali M, Zanola A, Venturelli E, Fenoglio C, Galimberti D, Scarpini E, Finazzi D.Polymorphisms in the LOC387715/ARMS2 Putative Gene and the Risk for Alzheimer's Disease. Dement Geriatr Cogn Disord. 2008;26(2):169-74. doi: 10.1159/000151050.

31. Borroni B, Ghezzi S, Agosti C, Archetti S, Fenoglio C, et al.Preliminary Evidence that VEGF Genetic Variability Confers Susceptibility to Frontotemporal Lobar Degeneration. Rejuvenation Res. 2008 Aug;11(4):773-80. doi: 10.1089/rej.2008.0711.

32. Cortini F, Fenoglio C,et al.Novel exon 1 progranulin gene variant in Alzheimer's disease. Eur J Neurol. 2008 Oct;15(10):1111-7. doi: 10.1111/j.1468-1331.2008.02266.x.

33. Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, et al . Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain. 2008 Nov;131(Pt 11):3081-91. doi: 10.1093/brain/awn217.

34. Albani D, Prato F, Fenoglio C et al Association study to evaluate the serotonin transporter and apolipoprotein E genes in frontotemporal lobar degeneration in Italy. Journal of Human Genetics 2008;53:1029-33.

35. Galimberti D, Fenoglio C, Scarpini E. Inflammation in neurodegenerative disorders: friend or foe? Curr. Aging Sci. 2008;1(1):30-41.

36. Venturelli E, Villa C, Fenoglio C, et al. The NOS3 G894T (Glu298Asp) polymorphism is a risk factor for frontotemporal lobar degeneration. Eur J Neurol 2009; 16: 37-42.

37. Fenoglio C, Scalabrini D, Piccio L, De Riz M, Venturelli E, Cortini F, Villa C, Serpente M, Parks B, Rinker J, Cross AH, Bresolin N, Scarpini E, Galimberti D. Candidate gene analysis of selectin cluster in patients with multiple sclerosis. J Neurol. 2009 May;256(5):832-3. doi: 10.1007/s00415-009-5016-7.

38. Villa C, Venturelli E, Fenoglio C, et al. CCL8/MCP-2 association analysis in patients with Alzheimer's disease and frontotemporal lobar degeneration. J Neurol. 2009;256:1379-81.

39. Villa C, Venturelli E, Fenoglio C, et al. DCUN1D1 is a risk factor for frontotemporal lobar degeneration. Eur J Neurol. 2009;16:870-873.

40. Galimberti D, Venturelli E, Villa C, Fenoglio C, et al. MCP-1 A-2518G polymorphism: effect on susceptibility for frontotemporal lobar degeneration and on cerebrospinal fluid MCP-1 levels. J Alzheimer’s Dis. 2009;17:125-33.

41. Fenoglio C, Galimberti D, Cortini F, Kauwe SJK, Cruchaga C, Venturelli E, Villa C, Serpente M, Scalabrini D, Mayo K, Piccio LM, Clerici F, Albani D, Mariani C, Forloni G, Bresolin N, Goate AM, Scarpini E. s5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. J Alzheimers Dis. 2009;18(3):603-12. doi: 10.3233/JAD-2009-1170.

42. Del Bo R, Corti S, Santoro D, Ghione I, Fenoglio C, et al. No major progranulin genetic variability contribution to disease etiopathogenesis in an ALS Italian cohort. Neurobiol Aging. 2011,32:1157-58.

43. Benussi L, Ghidoni R, Galimberti D, Boccardi M, Fenoglio C, Scarpini E, Frisoni GB, Binetti G. The CST3 B haplotype is associated with frontotemporal lobar degeneration. Eur J Neurol. 2010, 17:143-146.

44. Carecchio M, Fenoglio C, et al. Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease. J Neurol Sci. 2009. 287; 291-293.

45. Galimberti D, Fenoglio C, et al. GRN Variability Contributes to Sporadic Frontotemporal Lobar Degeneration. J Alzheimer's Dis. 2010;19(1):171-7.

46 Villa C, Venturelli E, Fenoglio C, et al. Candidate gene analysis of semaphorins in patients with Alzheimer's disease. D. J Neurol Sci. 2010; 31:169-173

47. De Riz M, Galimberti D, Fenoglio C, et al. Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. Neurosci Lett. 2010;469(2):234-6.

48. Comi C, Carecchio M, Chiocchetti A, Nicola S, Galimberti D, Fenoglio C, Cappellano G, Monaco F, Scarpini E, Dianzani U. Osteopontin is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease and Its Levels Correlate with Cognitive Decline. J Alzheimer's Dis.2010; 19:1143-48.

49. Cantoni C, Fenoglio C, et al. FUS/TLS Genetic Variability in Sporadic Frontotemporal Lobar Degeneration. J Alzheimer's Dis. 2010; 19:1317-1322.

50. Martinelli-Boneschi F, Esposito F, Scalabrini D, Fenoglio C, Rodegher ME, Brambilla P, Colombo B, Ghezzi A, Capra R, Collimedaglia L, Coniglio G, De Riz M, Serpente M, Cantoni C, Scarpini E, Martinelli V, Galimberti D, Comi G. Lack of replication of KIF1B gene in an Italian primary progressive multiple sclerosis cohort. Eur J Neurol. 2010; 17:740-745.

51. Mishto M, Bellavista E, Ligorio C, Textoris-Taube K, Santoro A, Giordano M, D'Alfonso S, Listì F, Nacmias B, Cellini E, Leone M, Grimaldi LM, Fenoglio C, et al. Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population. PLoS One 2010;2(5):e9287.

52. Lovati C, Galimberti D, Albani D, Bertora P, Venturelli E, Cislaghi G, Guidi I, Fenoglio C, Cortini F, Clerici F, Finazzi D, Forloni G, Scarpini E, Mariani C. APOE ε2 and ε4 influence the susceptibility for Alzheimer's disease but not other dementias. Int J Mol Epidemiol Genet. 2010;1(3):193-200

53. Fenoglio C, Scalabrini D, Esposito F, Comi C, Cavalla P, De Riz M, Martinelli V, Piccio LM, Venturelli E, Fumagalli G, Capra R, Collimedaglia L, Ghezzi A, Rodegher ME, Vercellino M, Leone M, Giordana MT, Bresolin N, Monaco F, Comi G, Scarpini E, Martinelli-Boneschi F, Galimberti D. Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. Genes & Immunity 2010;11(6):497-503. Genes Immun. 2010 Sep;11(6):497-503. doi: 10.1038/gene.2010.18.

54. Venturelli E, Villa C, Fenoglio C, et al. Is KIF24 a genetic risk factor for Frontotemporal Lobar Degeneration? Neurosci. Letters 2010;482:240-4.55. Cortini F, Fenoglio C, et al. Cell-dependent kinase inhibitor 2A and 2B genetic variability in patients with Alzheimer's disease. J. Neurol. 2011; 258: 704-705.

55.Venturelli E, Villa C, Fenoglio C, et al. BAG1 is a Protective Factor for Sporadic Frontotemporal Lobar Degeneration but not for Alzheimer's Disease. J Alzheimer's Disease 2011; 23:701-707.

56. Pietroboni AM, Fumagalli GG, Ghezzi L, Fenoglio C, et al. Phenotypic Heterogeneity of the GRN Asp22fs Mutation in a Large Italian Kindred. J Alzheimer's Disease 2011; 24: 253-259.

57. Ragheb S, Li Y, Simon K, Vanhaerents S, Galimberti D, De Riz M, Fenoglio C, Scarpini E, Lisak R. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Multiple Sclerosis 2011; 17(7): 819-829.

58. Galimberti D, Macmurray J, Scalabrini D, Fenoglio C, et al. GSK3β genetic variability in patients with Multiple Sclerosis. Neurosci. Lett. 2011; 497: 46-48.

59. Villa C, Fenoglio C, et al. Role of hnRNP-A1 and miR-590-3p in Neuronal Death: Genetics and Expression Analysis in Patients with Alzheimer Disease and Frontotemporal Lobar Degeneration. Rejuvenation Research 2011; 14(3): 275-81.

60. Villa C, Ghezzi L, Pietroboni AM, Fenoglio C, et al. A Novel MAPT Mutation Associated with the Clinical Phenotype of Progressive Nonfluent Aphasia. J Alzheimer's Disease 2011; 26: 19-26.

61. Serpente M, Fenoglio C, et al. Role of OLR1 and Its Regulating hsa-miR369-3p in Alzheimer's Disease: Genetics and Expression Analysis. J Alzheimer's Disease 2011; 26:787-793.

62. Fenoglio C, Cantoni C, De Riz M, Ridolfi E, Cortini F, Serpente M, Villa C, Comi C, Monaco F, Mellesi L, Valzelli S, Bresolin N, Galimberti D, Scarpini E. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci Lett. 2011 Oct 17;504(1):9-12. doi: 10.1016/j.neulet.2011.08.021.

63. Carecchio M, Fenoglio C, Cortini F, Comi C, Benussi L, Ghidoni R, Borroni B, De Riz M, Serpente M, Cantoni C, Franceschi M, Albertini V, Monaco F, Rainero I, Binetti G, Padovani A, Bresolin N, Scarpini E, Galimberti D. Cerebrospinal Fluid Biomarkers in Progranulin Mutations Carriers. J Alzheimer's Dis. 2011;27:781-790.

64. Caso F, Villa C, Fenoglio C, et al. The progranulin (GRN) Cys157LysfsX97 mutation is associated with nonfluent variant of primary progressive aphasia clinical phenotype. J Alzheimer's Dis. 2012;28:759-763.

65. Martinelli-Boneschi F, Fenoglio C, Brambilla P, Sorosina M, Giacalone G, Esposito F, Serpente M, Cantoni C, Ridolfi E, Rodegher M, Moiola L, Colombo B, De Riz M, Martinelli V, Scarpini E, Comi G, Galimberti D. MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci Lett. 2012;508:4-8.

66. Ghidoni R, Stoppani E, Rossi G, Piccoli E, Albertini V, Paterlini A, Glionna M, Pegoiani E, Agnati LF, Fenoglio C, Scarpini E, Galimberti D, Morbin M, Tagliavini F, Binetti G, Benussi L. Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: a multicenter Italian study. Neurodegener Dis. 2012;9:121-127.

67. Guerini FR, Cagliani R, Forni D, Agliardi C, Caputo D, Cassinotti A, Galimberti D, Fenoglio C, Biasin M, Asselta R, Scarpini E, Comi GP, Bresolin N, Clerici M, Sironi M. A functional variant in ERAP1 predisposes to multiple sclerosis. PLoS One. 2012;7(1):e29931.

68. Cagliani R, Guerini FR, Fumagalli M, Riva S, Agliardi C, Galimberti D, Pozzoli U, Goris A, Dubois B, Fenoglio C,et al. A trans-specific polymorphism in ZC3HAV1 is maintained by long-standing balancing selection and may confer susceptibility to multiple sclerosis. Mol Biol Evol. 2012;29(6):1599-1613.

69. D'Addario C, Dell'Osso B, Palazzo MC, Benatti B, Lietti L, Cattaneo E, Galimberti D, Fenoglio C, et al. Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. Neuropsychopharmacology. 2012;37:1647-55.

70. Galimberti D, Dell'Osso B, Fenoglio C, et al. Progranulin gene variability and plasma levels in bipolar disorder and schizophrenia. PLoS One. 2012;7(4):e32164.

71. Arighi A, Fumagalli GG, Jacini F, Fenoglio C, Ghezzi L, Pietroboni AM, De Riz M, Serpente M, Ridolfi E, Bonsi R, Bresolin N, Scarpini E, Galimberti D. Early onset behavioral variant frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: psychiatric clinical presentations. J Alzheimer's Dis. 2012;31:447-52.

72. Villa C, Ghezzi L, Fenoglio C, Clerici F, Marcone A, Benussi L, Ghidoni R, Gallone S, Serpente M, Cantoni C, Ridolfi E, Bonsi R, Cerami C, Cappa S, Binetti G, Franceschi M, Rainero I, Mariani C, Bresolin N, Scarpini E, Galimberti D. Genetics and Expression Analysis of the Specificity Protein 4 Gene (SP4) in Patients with Alzheimer's Disease and Frontotemporal Lobar Degeneration. J Alzheimer's Dis. 2012;31:537-42.

73. Galimberti D, D'Addario C, Dell'osso B, Fenoglio C, Marcone A, Cerami C, Cappa SF, Palazzo MC, Arosio B, Mari D, Maccarrone M, Bresolin N, Altamura AC, Scarpini E. Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. Neurol Sci. 2013; 34:899-903.

74. Tiloca C, Ticozzi N, Pensato V, Corrado L, Del Bo R, Bertolin C, Fenoglio C, et al. Screening of the PFN1 gene in sporadic amyotrophic lateral sclerosis and in frontotemporal dementia. Neurobiol Aging. 2013;34:1517.e9-10.

75. Fenoglio C, Ridolfi E, Galimberti D, Scarpini E. MicroRNAs, active players in the pathogenesis of Multiple Sclerosis. J Mol Sci. 2012 Oct 15;13(10):13227-39. doi: 10.3390/ijms131013227.

76. Villa C, Ridolfi E, Fenoglio C, et al. Expression of the transcription factor Sp1 and its regulatory hsa-miR-29b in peripheral blood mononuclear cells from patients with Alzheimer's disease. J Alzheimers Dis.2013;35:487-94.

77. Cerami C, Marcone A, Galimberti D, Zamboni M, Fenoglio C, Serpente M, Scarpini E, Cappa SF. Novel evidence of phenotypical variability in the hexanucleotide repeat expansion in chromosome 9. J Alzheimer's Dis. 2013;35:455-462.

78. Ridolfi E, Fenoglio C, et al. Expression and Genetic Analysis of MicroRNAs Involved in Multiple Sclerosis. Int J Mol Sci. 2013;14:4375-84.

79. Galimberti D, Fenoglio C, Serpente M, Villa C, Bonsi R, Arighi A, Fumagalli GG, Del Bo R, Bruni AC, Anfossi M, Clodomiro A, Cupidi C, Nacmias B, Sorbi S, Piaceri I, Bagnoli S, Bessi V, Marcone A, Cerami C, Cappa SF, Filippi M, Agosta F, Magnani G, Comi G, Franceschi M, Rainero I, Giordana MT, Rubino E, Ferrero P, Rogaeva E, Xi Z, Confaloni A, Piscopo P, Bruno G, Talarico G, Cagnin A, Clerici F, Dell'osso B, Comi GP, Altamura AC, Mariani C, Scarpini E. Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation. Biol Psychiatry. 2013 Sep 1;74(5):384-91. doi: 10.1016/j.biopsych.2013.01.031.

80. Arosio B, Abbate C, Galimberti D, Rossi PD, Inglese S, Fenoglio C, et al. GRN Thr272fs clinical heterogeneity: a case with atypical late onset presenting with a dementia with Lewy bodies phenotype. J Alzheimer's Dis. 2013;35:669-674.

81. Cerami C, Marcone A, Galimberti D, Villa C, Fenoglio C, Scarpini E, Cappa SF. Novel missense progranulin gene mutation associated with the semantic variant of primary progressive aphasia.J Alzheimer's Dis. 2013;36:415-420.

82. Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, SerpenteM, Villa C, Pietroboni A Naismith RT, Alvarez E, Parks BJ, Bresolin N, Cross AH, Piccio L, Galimberti D and Scarpini E. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis Mult Scler. 2013 Dec;19(14):1938-42. doi: 10.1177/1352458513485654.

83.Galimberti D, Arosio B, Fenoglio C. et al. Incomplete Penetrance of the C9ORF72 Hexanucleotide Repeat Expansions: Frequency in a Cohort of Geriatric Non-Demented Subjects. Journal of Alzheimer's Disease. J Alzheimers Dis. 2014;39(1):19-22. doi: 10.3233/JAD-131172.

84. Fenoglio C, Ridolfi E, Galimberti D, Scarpini E.An emerging role for long non-coding RNA dysregulation in neurological disorders. Int J Mol Sci. 2013 Oct 14;14(10):20427-42. doi: 10.3390/ijms141020427.

85. Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, Fenoglio C, Piaceri I, Archetti S, Bonvicini C, Gennarelli M, Turla M, Scarpini E, Sorbi S, Padovani A. Heterozygous TREM2 mutations in frontotemporal dementia.Neurobiol Aging. 2014 Apr;35(4):934.e7-10. Doi 10.1016/j.neurobiolaging.2013.09.017.

86. Lambert JC, et al. (Fenoglio member of EADI group) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.Nat Genet. 2013 Dec;45(12):1452-8. doi: 10.1038/ng.2802. Epub 2013 Oct 27.

87. Carecchio M, Galimberti D, Fenoglio C, Serpente M, Scarpini E, Comi C, Terazzi E, Cantello R. Evidence of pre-synaptic dopaminergic deficit in a patient with a novel progranulin mutation presenting with atypical parkinsonism. J Alzheimers Dis. 2014;38(4):747-52. doi: 10.3233/JAD-131151.

88. Galimberti D, Reif A, Dell'Osso B, Palazzo C, Villa C, Fenoglio C, Kittel-Schneider S, Leonhard C, Olmes DG, Serpente M, Paoli RA, Altamura AC, Scarpini E. C9ORF72 hexanucleotide repeat expansion as a rare cause of bipolar disorder. Bipolar Disord. 2014 Jun;16(4):448-9. doi: 10.1111/bdi.12169. Epub 2013 Dec 16.

89. Guerini FR, Clerici M, Cagliani R, Malhotra S, Montalban X, Forni D, Agliardi C, Riva S, Caputo D, Galimberti D, Asselta R, Fenoglio C, Scarpini E, Comi GP, Bresolin N, Comabella M, Sironi M. No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosis.J Neuroimmunol. 2014 Jun 15;271(1-2):49-52. doi: 10.1016/j.jneuroim.2014.04.006.

90. Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, Dobson-Stone C, Brooks WS, Schofield PR, Halliday GM, Hodges JR, Piguet O, Bartley L, Thompson E, Haan E, Hernández I, Ruiz A, Boada M, Borroni B, Padovani A, Cruchaga C, Cairns NJ, Benussi L, Binetti G, Ghidoni R, Forloni G, Galimberti D, Fenoglio C, et al., Frontotemporal dementia and its subtypes: a genome-wide association study.Lancet Neurol. 2014 Jul;13(7):686-99. doi: 10.1016/S1474-4422(14)70065-1.

91. Dell'Osso B, D'Addario C, Carlotta Palazzo M, Benatti B, Camuri G, Galimberti D, Fenoglio C, et al. Epigenetic modulation of BDNF gene: differences in DNA methylation between unipolar and bipolar patients. J Affect Disord. 2014 Sep;166:330-3. doi: 10.1016/j.jad.2014.05.020. Epub 2014 May 23.

92. Galimberti D, Prunas C, Paoli RA, Dell'Osso B, Fenoglio C,et al. Progranulin gene variability influences the risk for bipolar I disorder, but not bipolar II disorder. Bipolar Disord. 2014 Nov;16(7):769-72. doi: 10.1111/bdi.12180. Epub 2014 Feb 6.

93. Lattante S, Le Ber I, Galimberti D, Serpente M, Rivaud-Péchoux S, Camuzat A, Clot F, Fenoglio C. et al. Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and C9orf72 repeat expansions. Neurobiol Aging. 2014 Nov;35(11):2658.e1-2658.e5. doi: 10.1016/j.neurobiolaging.2014.06.023.

94. Abbate C, Arosio B, Galimberti D, Nicolini P, Chiara LR, Rossi PD, Ferri E, Gussago C, Deriz M, Fenoglio C, Serpente M, Scarpini E, Mari D. Phenotypic variability associated with the C9ORF72 hexanucleotide repeat expansion: a sporadic case of frontotemporal lobar degeneration with prodromal hyposmia and predominant semantic deficits. J Alzheimers Dis. 2014;40(4):849-55. doi: 10.3233/JAD-132075.

95. Fenoglio C, De Riz M, Villa C, Serpente M, Ridolfi E, Bonsi R, Cioffi SM, Barone C, Pietroboni A, Calvi A, Scarpini E, Galimberti D. C9ORF72 repeat expansion not detected in patients with multiple sclerosis. Neurobiol Aging. 2014 May;35(5):1213.e1-2. doi: 10.1016/j.neurobiolaging.2013.10.096. Epub 2013 Nov 1. PMID: 24355526.

96. Gallone S, Boschi S, Rubino E, De Martino P, Scarpini E, Galimberti D, Fenoglio C, Acutis PL, Maniaci MG, Pinessi L, Rainero I. Is HCRTR2 a genetic risk factor for Alzheimer's disease? Dement Geriatr Cogn Disord. 2014;38(3-4):245-53. doi: 10.1159/000359964. Epub 2014 Jun 25. PMID: 24969517.

97. Serpente M, Fenoglio C, et al. Transmembrane protein 106B gene (TMEM106B) variability and influence on progranulin plasma levels in patients with Alzheimer's disease. J Alzheimers Dis. 2015;43(3):757-61. doi: 10.3233/JAD-141167.

98. Talarico G, Canevelli M, Tosto G, Piscopo P, Confaloni A, Galimberti D, Fenoglio C, Scarpini E, Gasparini M, Bruno G. Binge eating and fast cognitive worsening in an early-onset bvFTD patient carrying C9ORF72 expansion. Neurocase. 2015;21(5):543-7. doi: 10.1080/13554794.2014.951056. Epub 2014 Aug 26.

99. Calvi A, Cioffi SM, Caffarra P, Fenoglio C, Serpente M, Pietroboni AM, Arighi A, Ghezzi L, Gardini S, Scarpini E, Galimberti D. The novel GRN g.1159_1160delTG mutation is associated with behavioral variant frontotemporal dementia. J Alzheimers Dis. 2015;44(1):277-82. doi: 10.3233/JAD-141380.

100. Galimberti D, Reif A, Dell'osso B, Kittel-Schneider S, Leonhard C, Herr A, Palazzo C, Villa C, Fenoglio C, Serpente M, Cioffi SM, Prunas C, Paoli RA, Altamura AC, Scarpini E. C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia. Neurobiol Aging. 2014 May;35(5):1214.e7-1214.e10. doi: 10.1016/j.neurobiolaging.2013.12.004. Epub 2013 Dec 11. PMID: 24387986.

101. Galimberti D, Villa C, Fenoglio C, Serpente M, Ghezzi L, Cioffi SM, Arighi A, Fumagalli G, Scarpini E. Circulating miRNAs as potential biomarkers in Alzheimer's disease. J Alzheimers Dis. 2014;42(4):1261-7. doi: 10.3233/JAD-140756. PMID: 25024331.

102. Piscopo P, Tosto G, Belli C, Talarico G, Galimberti D, Gasparini M, Canevelli M, Poleggi A, Crestini A, Albani D, Forloni G, Lucca U, Quadri P, Tettamanti M, Fenoglio C, Scarpini E, Bruno G, Vanacore N, Confaloni A. SORL1 Gene is Associated with the Conversion from Mild Cognitive Impairment to Alzheimer's Disease. J Alzheimers Dis. 2015;46(3):771-6. doi: 10.3233/JAD-141551.

103. Serpente M, Fenoglio C, et al. Profiling of ubiquitination pathway genes in peripheral cells from patients with frontotemporal dementia due to C9ORF72 and GRN mutations. Int J Mol Sci. 2015 Jan 8;16(1):1385-94. doi: 10.3390/ijms16011385.

104. Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C,et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.Mult Scler. 2015 Jul;21(8):1013-24. doi: 10.1177/1352458514568827. Epub 2015 Feb 13.PMID: 25680984

105. Galimberti D, Bonsi R, Fenoglio C, et al. Inflammatory molecules in Frontotemporal Dementia: cerebrospinal fluid signature of progranulin mutation carriers. Brain Behav Immun. 2015 Oct;49:182-7. doi: 10.1016/j.bbi.2015.05.006. Epub 2015 May 27.

106. Arighi A, Rango M, Bozzali M, Pietroboni AM, Fumagalli G, Ghezzi L, Fenoglio C, Biondetti PR, Bresolin N, Galimberti D, Scarpini E. Usefulness of Multi-Parametric MRI for the Investigation of Posterior Cortical Atrophy. PLoS One. 2015 Oct 19;10(10):e0140639. doi10.1371/journal.pone.0140639. eCollection 2015.

107. Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK, Carecchio M, Reid E, Heslegrave A, Fenoglio C, Scarpini E, Schott JM, Fox NC, Hardy J, Bhatia K, Heales S, Sebire NJ, Zetterberg H, Mills K. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegener. 2015 Dec 1;10:64. doi: 10.1186/s13024-015-0059-y.

108. Oldoni E, Fumagalli GG, Serpente M, Fenoglio C, Scarioni M, Arighi A, Bruno G, Talarico G, Confaloni A, Piscopo P, Nacmias B, Sorbi S, Rainero I, Rubino E, Pinessi L, Binetti G, Ghidoni R, Benussi L, Grande G, Arosio B, Bursey D, Kauwe JS, Cioffi SM, Arcaro M, Mari D, Mariani C, Scarpini E,

Galimberti D. PRNP P39L Variant is a Rare Cause of Frontotemporal Dementia in Italian Population. J Alzheimers Dis. 2016;50(2):353-7. doi: 10.3233/JAD-150863. PMID: 26757195

109. Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, Runia T, Evdoshenko E, Thouvenot E, Trojano M, Norgren N, Teunissen C, Kappos L, Giovannoni G, Kuhle J; International Clinically Isolated Syndrome Study Group. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):126-9. doi: 10.1136/jnnp-2014-309690. Epub 2015 Feb 25. PMID: 25716934

110. Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK, Carecchio M, Reid E, Heslegrave A, Fenoglio C, Scarpini E, Schott JM, Fox NC, Hardy J, Bhatia KP, Heales S, Sebire NJ, Zetterberg H, Mills K. Erratum to: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegener. 2016 Feb 23;11:20. doi: 10.1186/s13024-016-0086-3.PMID: 26907468

111. Ferri E, Arosio B, D'Addario C, Galimberti D, Gussago C, Pucci M, Casati M, Fenoglio C, Abbate C, Rossi PD, Scarpini E, Maccarrone M, Mari D. Gene promoter methylation and expression of Pin1 differ between patients with frontotemporal dementia and Alzheimer's disease. J Neurol Sci. 2016 Mar 15;362:283-6. doi: 10.1016/j.jns.2016.02.004. Epub 2016 Feb 3. PMID: 26944164

112. Clarelli F, Mascia E, Santangelo R, Mazzeo S, Giacalone G, Galimberti D, Fusco F, Zuffi M, Fenoglio C, Franceschi M, Scarpini E, Forloni G, Magnani G, Comi G, Albani D, Martinelli Boneschi F. CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients. J Alzheimers Dis. 2016 Apr 16;52(4):1203-8. doi: 10.3233/JAD-160074. PMID: 27104904

113. Galimberti D, Bertram K, Formica A, Fenoglio C, Cioffi SM, Arighi A, Scarpini E, Colosimo C. Plasma Screening for Progranulin Mutations in Patients with Progressive Supranuclear Palsy and Corticobasal Syndromes. J Alzheimers Dis. 2016 May 4;53(2):445-9. doi: 10.3233/JAD-160073. PMID: 27163816

114. Piccio L, Deming Y, Del-Águila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016 Jun;131(6):925-33. doi: 10.1007/s00401-016-1533-5. Epub 2016 Jan 11. PMID: 26754641

115. Neven KY, Piola M, Angelici L, Cortini F, Fenoglio C, Galimberti D, Pesatori AC, Scarpini E, Bollati V. Repetitive element hypermethylation in multiple sclerosis patients. BMC Genet. 2016 Jun 18;17(1):84. doi: 10.1186/s12863-016-0395-0. PMID: 27317098

116. Vercellino M, Fenoglio C, et al.Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis. Mult Scler. 2016 Jul;22(8):1007-12. doi: 10.1177/1352458515610646. Epub 2015 Oct 7. PMID: 26447062

117. Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, Ghidoni R, Pijnenburg YA, Borroni B, Galimberti D, Laforce RJ, Masellis M, Vandenberghe R, Ber IL, Otto M, van Minkelen R, Papma JM, Rombouts SA, Balasa M, Öijerstedt L, Jelic V, Dick KM, Cash DM, Harding SR, Jorge Cardoso M, Ourselin S, Rossor MN, Padovani A, Scarpini E, Fenoglio C, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016 Jul 1;3(8):623-36. doi: 10.1002/acn3.325. eCollection 2016 Aug. PMID: 27606344

118 Cioffi SM, Galimberti D, Barocco F, Spallazzi M, Fenoglio C, Serpente M, Arcaro M, Gardini S, Scarpini E, Caffarra P. Non Fluent Variant of Primary Progressive Aphasia Due to the Novel GRN g.9543delA(IVS3-2delA) Mutation. J Alzheimers Dis. 2016 Sep 6;54(2):717-21. doi: 10.3233/JAD-160185. PMID: 27567822

119. Fenoglio C, De Riz M, Pietroboni AM, Calvi A, Serpente M, Cioffi SM, Arcaro M, Oldoni E, Scarpini E, Galimberti D. Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis. J Neuroimmunol. 2016 Oct 15;299:81-83. doi: 10.1016/j.jneuroim.2016.08.017. Epub 2016 Aug 31. PMID: 27725128

120. Sainaghi PP, Bellan M, Lombino F, Alciato F, Carecchio M, Galimberti D, Fenoglio C, Scarpini E, Cantello R, Pirisi M, Comi C. Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. J Alzheimers Dis. 2017;55(1):59-65. doi: 10.3233/JAD-160599. PMID: 27636849

121. van Waalwijk van Doorn LJ, Gispert JD, Kuiperij HB, Claassen JA, Arighi A, Baldeiras I, Blennow K, Bozzali M, Castelo-Branco M, Cavedo E, Emek-Savaş DD, Eren E, Eusebi P, Farotti L, Fenoglio C,et al. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. J Alzheimers Dis. 2017;56(2):543-555. doi: 10.3233/JAD-160668. PMID: 28059783

122. Ferrari R,et al (Fenoglio C. member of the IGAP group). J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):152-164. doi: 10.1136/jnnp-2016-314411. Epub 2016 Nov 29. PMID: 27899424

123. Galimberti D, Cioffi SM, Fenoglio C, Serpente M, Oblak AL, Rodriguez-Porcel F, Oldoni E, Hagen MC, Arcaro M, Scarpini E, Ghetti B, Espay AJ. Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation. Mov Disord. 2017 Mar;32(3):476-478. doi: 10.1002/mds.26872. Epub 2016 Nov 15. PMID: 27859661

124. Dianzani C, Bellavista E, Liepe J, Verderio C, Martucci M, Santoro A, Chiocchetti A, Gigliotti CL, Boggio E, Ferrara B, Riganti L, Keller C, Janek K, Niewienda A, Fenoglio C, et al. Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. Sci Rep. 2017 Mar 9;7:43718. doi: 10.1038/srep43718. PMID: 28276434.

125. Sudre CH et al (Fenoglio C. member of the GENFI group). White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. Neuroimage Clin. 2017 Apr 26;15:171-180. doi: 10.1016/j.nicl.2017.04.015. eCollection 2017. PMID: 28529873

126. Mishra A, et al (Fenoglio C. member of the FTD-Genomics Consortium. Gene-based association studies report genetic links for clinical subtypes of frontotemporal dementia. Brain. 2017 May 1;140(5):1437-1446. doi: 10.1093/brain/awx066. PMID: 28387812

127. Premi E, et al. Genetic FTD Initiative (GENFI). Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain. 2017 Jun 1;140(6):1784-1791. doi: 10.1093/brain/awx103. PMID: 28460069

128. Pietroboni AM, Schiano di Cola F, Scarioni M, Fenoglio C, Spanò B, Arighi A, Cioffi SM, Oldoni E, De Riz MA, Basilico P, Calvi A, Fumagalli GG, Triulzi F, Galimberti D, Bozzali M, Scarpini E. CSF ß-amyloid as a putative biomarker of disease progression in multiple sclerosis. Mult Scler. 2017 Jul;23(8):1085-1091. doi: 10.1177/1352458516674566. Epub 2016 Oct 17. PMID: 27754941

129. Taskesen E, Mishra A, van der Sluis S, Ferrari R; International FTD-Genomics Consortium; Veldink JH, van Es MA, Smit AB, Posthuma D, Pijnenburg Y. Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS. Sci Rep. 2017 Aug 21;7(1):8899. doi: 10.1038/s41598-017-09320-z. PMID: 28827549

130 Paroni M, Maltese V, De Simone M, Ranzani V, Larghi P, Fenoglio C, et al. Recognition of viral and self-antigens by TH1 and TH1/TH17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses. J Allergy Clin Immunol. 2017 Sep;140(3):797-808. doi: 10.1016/j.jaci.2016.11.045. Epub 2017 Feb 22.PMID: 28237728

131. Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER, Grenier-Boley B, Heilmann-Heimbach S, Chouraki V, Kuzma AB, Sleegers K, Vronskaya M, Ruiz A, Graham RR, Olaso R, Hoffmann P, Grove ML, Vardarajan BN, Hiltunen M, Nöthen MM, White CC, Hamilton-Nelson KL, Epelbaum J, Maier W, Choi SH, Beecham GW, Dulary C, Herms S, Smith AV, Funk CC, Derbois C, Forstner AJ, Ahmad S, Li H, Bacq D, Harold D, Satizabal CL, Valladares O, Squassina A, Thomas R, Brody JA, Qu L, Sánchez-Juan P, Morgan T, Wolters FJ, Zhao Y, Garcia FS, Denning N, Fornage M, Malamon J, Naranjo MCD, Majounie E, Mosley TH,

Dombroski B, Wallon D, Lupton MK, Dupuis J, Whitehead P, Fratiglioni L, Medway C, Jian X, Mukherjee S, Keller L, Brown K, Lin H, Cantwell LB, Panza F, McGuinness B, Moreno-Grau S, Burgess JD, Solfrizzi V, Proitsi P, Adams HH, Allen M, Seripa D, Pastor P, Cupples LA, Price ND, Hannequin D, Frank-García A, Levy D, Chakrabarty P, Caffarra P, Giegling I, Beiser AS, Giedraitis V, Hampel H, Garcia ME, Wang X, Lannfelt L, Mecocci P, Eiriksdottir G, Crane PK, Pasquier F, Boccardi V, Henández I, Barber RC, Scherer M, Tarraga L, Adams PM, Leber M, Chen Y, Albert MS, Riedel-Heller S, Emilsson V, Beekly D, Braae A, Schmidt R, Blacker D, Masullo C, Schmidt H, Doody RS, Spalletta G, Longstreth WT Jr, Fairchild TJ, Bossù P, Lopez OL, Frosch MP, Sacchinelli E, Ghetti B, Yang Q, Huebinger RM, Jessen F, Li S, Kamboh MI, Morris J, Sotolongo-Grau O, Katz MJ, Corcoran C, Dunstan M, Braddel A, Thomas C, Meggy A, Marshall R, Gerrish A, Chapman J, Aguilar M, Taylor S, Hill M, Fairén MD, Hodges A, Vellas B, Soininen H, Kloszewska I, Daniilidou M, Uphill J, Patel Y, Hughes JT, Lord J, Turton J, Hartmann AM, Cecchetti R, **Fenoglio C**,et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet. 2017 Sep;49(9):1373-1384. doi: 10.1038/ng.3916. Epub 2017 Jul 17.PMID: 28714976

132. Ghezzi L, Carandini T, Arighi A, Fenoglio C, et al. Evidence of CNS ß-amyloid deposition in Nasu-Hakola disease due to the TREM2 Q33X mutation. Neurology. 2017 Dec 12;89(24):2503-2505. doi: 10.1212/WNL.0000000000004747. Epub 2017 Nov 15.PMID: 29142083

133. Mutsaerts HJMM, et al. (Fenoglio C part of the GENFI investigators). Comparison of arterial spin labeling registration strategies in the multi-center GENetic frontotemporal dementia initiative (GENFI). J Magn Reson Imaging. 2018 Jan;47(1):131-140. doi: 10.1002/jmri.25751. Epub 2017 May 8. PMID: 28480617

134. Arighi A, Carandini T, Mercurio M, Carpani G, Pietroboni AM, Fumagalli G, Ghezzi L, Basilico P, Calvi A, Scarioni M, De Riz M, Fenoglio C, Scola E, Triulzi F, Galimberti D, Scarpini E. Word and Picture Version of the Free and Cued Selective Reminding Test (FCSRT): Is There Any Difference? J Alzheimers Dis. 2018;61(1):47-52. doi: 10.3233/JAD-170712. PMID: 29125489

135. Serpente M, Fenoglio C,et al. Profiling of Specific Gene Expression Pathways in Peripheral Cells from Prodromal Alzheimer's Disease Patients. J Alzheimers Dis. 2018;61(4):1289-1294. doi: 10.3233/JAD-170861. PMID: 29376874

136. Fenoglio C, Scarpini E, Serpente M, Galimberti D. Role of Genetics and Epigenetics in the Pathogenesis of Alzheimer's Disease and Frontotemporal Dementia. J Alzheimers Dis. 2018;62(3):913-932. doi: 10.3233/JAD-170702. PMID: 29562532

137. Di Battista ME, Dell'Acqua C, Baroni L, Fenoglio C, Galimberti D, Gallucci M. Frontotemporal Dementia Misdiagnosed for Post-Treatment Lyme Disease Syndrome or vice versa? A Treviso Dementia (TREDEM) Registry Case Report. J Alzheimers Dis. 2018;66(2):445-451. doi: 10.3233/JAD-180524. PMID: 30282363.

138. roce I, et al. (Fenoglio C member of the intenational FTD –Genetic consortium) .Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies.PLoS Med. 2018 Jan 9;15(1):e1002487. doi: 10.1371/journal.pmed.1002487. eCollection 2018 Jan.PMID: 29315334

139. Galimberti D, Fumagalli GG, Fenoglio C,et al. Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiol Aging. 2018 Feb;62:245.e9-245.e12. doi 10.1016/j.neurobiolaging.2017.10.016.

140. Cash DM, et al.(Fenoglio C member of the GENFI consortium). Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiol Aging. 2018 Feb;62:191-196. doi: 10.1016/j.neurobiolaging.2017.10.008. Epub 2017 Oct 19. PMID: 29172163

141. D'Addario C, Palazzo MC, Benatti B, Grancini B, Pucci M, Di Francesco A, Camuri G, Galimberti D, Fenoglio C, Scarpini E, Altamura AC, Maccarrone M, Dell'Osso B. Regulation of gene transcription in bipolar disorders: Role of DNA methylation in the relationship between prodynorphin and brain derived

neurotrophic factor. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:314-321. doi: 10.1016/j.pnpbp.2017.08.011. Epub 2017 Aug 19.

142. Pietroboni AM, Scarioni M, Carandini T, Basilico P, Cadioli M, Giulietti G, Arighi A, Caprioli M, Serra L, Sina C, Fenoglio C, et al. CSF ß-amyloid and white matter damage: a new perspective on Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):352-357. doi: 10.1136/jnnp-2017-316603. Epub 2017 Oct 20. PMID: 29054920

143. Bonham LWet al (Fenoglio C. member of the IGAP). CXCR4 involvement in neurodegenerative diseases.Transl Psychiatry. 2018 Apr 11;8(1):73. doi: 10.1038/s41398-017-0049-7.PMID: 29636460

144. Calogero AM, Viganò M, Budelli S, Galimberti D, Fenoglio C, et al. Microtubule defects in mesenchymal stromal cells distinguish patients with Progressive Supranuclear Palsy. J Cell Mol Med. 2018 May;22(5):2670-2679. doi: 10.1111/jcmm.13545. Epub 2018 Mar 4.PMID: 29502334

145. Taskesen E, Mishra A, van der Sluis S, Ferrari R; International FTD-Genomics Consortium. Author Correction: Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS. Sci Rep. 2018 May 14;8(1):7789. doi: 10.1038/s41598-018-21308-x. PMID: 29760392

146. Fumagalli GG, Basilico P, Arighi A, Bocchetta M, Dick KM, Cash DM, Harding S, Mercurio M, Fenoglio C,et al . Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. Alzheimers Res Ther. 2018 May 24;10(1):46. doi: 10.1186/s13195-018-0376-9. PMID: 29793546

147. Fenoglio C, Scarpini E, Galimberti D. Epigenetic regulatory modifications in genetic and sporadic frontotemporal dementia. Expert Rev Neurother. 2018 Jun;18(6):469-475. doi: 10.1080/14737175.2018.1481389. Epub 2018 Jun 5. PMID: 29799291

148. Galimberti D, Fenoglio C, Scarpini E. Progranulin as a therapeutic target for dementia. Expert Opin Ther Targets. 2018 Jul;22(7):579-585. doi: 10.1080/14728222.2018.1487951. Epub 2018 Jun 22. PMID: 29889573

149. Schneider R, et al (Fenoglio C member of the GENFI). Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):851-858. doi: 10.1136/jnnp-2017-317492. Epub 2018 Feb 6. PMID: 29434051

150. Jiskoot LC,et al (Fenoglio C member of the GENFI). Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: A cross-sectional diffusion tensor imaging study. Ann Clin Transl Neurol. 2018 Jul 11;5(9):1025-1036. doi: 10.1002/acn3.601. eCollection 2018 Sep. PMID: 30250860

151. Peloso GM, van der Lee SJ; International Genomics of Alzheimer's Project (IGAP); Destefano AL, Seshardi S. Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. Alzheimers Dement (Amst). 2018 Sep 22;10:595-598. doi: 10.1016/j.dadm.2018.08.008. eCollection 2018. PMID: 30422133

152. Zhang M,et al. (Fenoglio member of the International FTD-Genomics Consortium (IFGC)). A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain. 2018 Oct 1;141(10):2895-2907. doi: 10.1093/brain/awy238.

153. Young AL, (Fenoglio member of the GENFI); Alzheimer’s Disease Neuroimaging Initiative (ADNI). Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nat Commun. 2018 Oct 15;9(1):4273. doi: 10.1038/s41467-018-05892-0. PMID: 30323170

154. Fenoglio C, Oldoni E, Serpente M, De Riz MA, Arcaro M, D'Anca M, Pietroboni AM, Calvi A, Lecchi E, Goris A, Mallants K, Dubois B, Comi C, Cantello R, Scarpini E, Galimberti D. LncRNAs expression

profile in peripheral blood mononuclear cells from multiple sclerosis patients.. J Neuroimmunol. 2018 Nov 15;324:129-135. doi: 10.1016/j.jneuroim.2018.08.008. Epub 2018 Aug 27. PMID: 30170791

155. Heywood WE, Hallqvist J, Heslegrave AJ, Zetterberg H, Fenoglio C, Scarpini E, Rohrer JD, Galimberti D, Mills K. CSF pro-orexin and amyloid-ß38 expression in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging. 2018 Dec;72:171-176. Doi 10.1016/j.neurobiolaging.2018.08.019. Epub 2018 Aug 25. PMID: 30292090

156. Swarup V, et al. (Fenoglio C. member of the International Frontotemporal Dementia Genomics Consortium); Grossman M, Van Deerlin VM, Trojanowski JQ, Lah JJ, Levey AI, Kondou S, Geschwind DH. Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nat Med. 2019 Jan;25(1):152-164. doi: 10.1038/s41591-018-0223-3. Epub 2018 Dec 3. PMID: 30510257

157. Fumagalli GG, Sacchi L, Basilico P, Arighi A, Carandini T, Scarioni M, Colombi A, Pietroboni A, Ghezzi L, Fenoglio C, et al. Monozygotic Twins with Frontotemporal Dementia Due To Thr272fs GRN Mutation Discordant for Age At Onset. J Alzheimers Dis. 2019;67(4):1173-1179. doi: 10.3233/JAD-180723. PMID: 30689572

158. Gallucci M, Dell'Acqua C, Bergamelli C, Fenoglio C, Serpente M, Galimberti D, Fiore V, Medea S, Gregianin M, Di Battista ME. A Case with Early Onset Alzheimer's Disease, Frontotemporal Hypometabolism, ApoE Genotype ε4/ε4 and C9ORF72 Intermediate Expansion: A Treviso Dementia (TREDEM) Registry Case Report. J Alzheimers Dis. 2019;67(3):985-993. doi: 10.3233/JAD-180715. PMID: 30714955

159. Gallucci M, Dell'Acqua C, Boccaletto F, Fenoglio C, Galimberti D, Di Battista ME. Overlap Between Frontotemporal Dementia and Dementia with Lewy Bodies: A Treviso Dementia (TREDEM) Registry Case Report. J Alzheimers Dis. 2019;69(3):839-847. doi: 10.3233/JAD-181298. PMID: 31127780

160. Arighi A, Di Cristofori A, Fenoglio C, Borsa S, D'Anca M, Fumagalli GG, Locatelli M, Carrabba G, Pietroboni AM, Ghezzi L, Carandini T, Colombi A, Scarioni M, De Riz MA, Serpente M, Rampini PM, Scarpini E, Galimberti D. Cerebrospinal Fluid Level of Aquaporin4: A New Window on Glymphatic System Involvement in Neurodegenerative Disease? J Alzheimers Dis. 2019;69(3):663-669. doi: 10.3233/JAD-190119. PMID: 31156164

161. Sudre CH, et al. (Fenoglio C member of GENFI). White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study.Neuroimage Clin. 2019;24:102077. doi: 10.1016/j.nicl.2019.102077. Epub 2019 Nov 6. PMID: 31835286

162. Pietroboni AM, Carandini T, Colombi A, Mercurio M, Ghezzi L, Giulietti G, Scarioni M, Arighi A, Fenoglio C, et al. Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF ß-amyloid levels and brain volumes. Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):280-287. doi: 10.1007/s00259-018-4182-1. Epub 2018 Oct 21. PMID: 30343433

163. Cury C, et al. (Fenoglio C member of GENFI). Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. Neuroimage. 2019 Mar;188:282-290. doi: 10.1016/j.neuroimage.2018.11.063. Epub 2018 Dec 6. PMID: 30529631

164. Galimberti D, Fenoglio C, et al. Inflammatory expression profile in peripheral blood mononuclear cells from patients with Nasu-Hakola Disease. Cytokine. 2019 Apr;116:115-119. doi: 10.1016/j.cyto.2018.12.024. Epub 2019 Jan 25. PMID: 30690291

165. Premi E, et al.(Fenoglio C member of GENFI) . The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. Neuroimage. 2019 Apr 1;189:645-654. doi: 10.1016/j.neuroimage.2019.01.080. Epub 2019 Feb 1. PMID: 30716457

166. Mutsaerts HJMM, et al (Fenoglio member of the GENFI). Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain. 2019 Apr 1;142(4):1108-1120. doi: 10.1093/brain/awz039. PMID: 30847466

167. Massaccesi L, Galliera E, Galimberti D, Fenoglio C, Arcaro M, Goi G, Barassi A, Corsi Romanelli MM. Lag-time in Alzheimer's disease patients: a potential plasmatic oxidative stress marker associated with ApoE4 isoform. Immun Ageing. 2019 Apr 1;16:7. doi: 10.1186/s12979-019-0147-x. eCollection 2019. PMID: 30984280

168. Rittman T, et al (Fenoglio member of the GENFI). Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiol Aging. 2019 May;77:169-177. doi: 10.1016/j.neurobiolaging.2018.12.009. Epub 2019 Jan 4. PMID: 30831384

169. D'Addario C, Bellia F, Benatti B, Grancini B, Vismara M, Pucci M, De Carlo V, Viganò C, Galimberti D, Fenoglio C, Scarpini E, Maccarrone M, Dell'Osso B. Exploring the role of BDNF DNA methylation and hydroxymethylation in patients with obsessive compulsive disorder. J Psychiatr Res. 2019 Jul;114:17-23. doi: 10.1016/j.jpsychires.2019.04.006. Epub 2019 Apr 6. PMID: 31004918

170. Bonham LW, et al (Fenoglio member of the International FTD-Genomics Consortium (IFGC). Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia. Sci Rep. 2019 Jul 26;9(1):10854. doi: 10.1038/s41598-019-46415-1. PMID: 31350420

171. Pietroboni AM, Caprioli M, Carandini T, Scarioni M, Ghezzi L, Arighi A, Cioffi S, Cinnante C, Fenoglio C, et al. CSF ß-amyloid predicts prognosis in patients with multiple sclerosis. Mult Scler. 2019 Aug;25(9):1223-1231. doi: 10.1177/1352458518791709. Epub 2018 Aug 7. PMID: 30084711

172. D'Anca M, Fenoglio C, Serpente M, Arosio B, Cesari M, Scarpini EA, Galimberti D. Exosome Determinants of Physiological Aging and Age-Related Neurodegenerative Diseases. Front Aging Neurosci. 2019 Aug 28;11:232. doi: 10.3389/fnagi.2019.00232. eCollection 2019. PMID: 31555123

173. Carandini T, Arighi A, Sacchi L, Fumagalli GG, Pietroboni AM, Ghezzi L, Colombi A, Scarioni M, Fenoglio C, et al. Alzheimers Res Ther. 2019 Oct 15;11(1):84. doi: 10.1186/s13195-019-0543-7. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes

174. Tavares TP, et al (Fenoglio C member of the GENFI). GENFIVentricular volume expansion in presymptomatic genetic frontotemporal dementia. Neurology. 2019 Oct 29;93(18):e1699-e1706. doi: 10.1212/WNL.0000000000008386. Epub 2019 Oct 2.

175. van der Ende EL,(Fenoglio C member of the GENFI); Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Genetic Frontotemporal dementia Initiative (GENFI). Lancet Neurol. 2019 Dec;18(12):1103-1111. doi: 10.1016/S1474-4422(19)30354-0.

176. Pietroboni AM, Colombi A, Carandini T, Contarino VE, Ghezzi L, Fumagalli GG, Arighi A, Fenoglio C, De Riz MA, Triulzi F, Scarpini E, Galimberti D. Low CSF ß-amyloid levels predict early regional grey matter atrophy in multiple sclerosis. Mult Scler Relat Disord. 2019 Dec 19;39:101899. doi: 10.1016/j.msard.2019.101899. PMID: 31884385

177. Rubino E, Di Stefano M, Galimberti D, Serpente M, Scarpini E, Fenoglio C, Bo M, Rainero I. C9ORF72 hexanucleotide repeat expansion frequency in patients with Paget's disease of bone. Neurobiol Aging. 2020 Jan;85:154.e1-154.e3. doi: 10.1016/j.neurobiolaging.2019.08.014.PMID: 31530427

178. Pietroboni AM, Schiano di Cola F, Colombi A, Carandini T, Fenoglio C,et al. CSF ß-amyloid predicts early cerebellar atrophy and is associated with a poor prognosis in multiple sclerosis. Mult Scler Relat Disord. 2020 Jan;37:101462. doi: 10.1016/j.msard.2019.101462.

179. Gallucci M, Pallucca C, Di Battista ME, Bergamelli C, Fiore V, Boccaletto F, Fiorini M, Perra D, Zanusso G, Fenoglio C, Serpente M, Galimberti D, Bonanni L. Anti-Cholinergic Derangement of Cortical Metabolism on 18F-FDG PET in a Patient with Frontotemporal Lobar Degeneration Dementia: A Case of the TREDEM Registry. J Alzheimers Dis. 2020;74(4):1107-1117. doi: 10.3233/JAD-191290.

180. Moore KM, et al (Fenoglio C member of the FTD Prevention Initiative). Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol. 2020 Feb;19(2):145-156. doi: 10.1016/S1474-4422(19)30394-1. Epub 2019 Dec 3.

181. Carlini V, Verduci I, Cianci F, Cannavale G, Fenoglio C, Galimberti D, Mazzanti M. CLIC1 Protein Accumulates in Circulating Monocyte Membrane during Neurodegeneration. Int J Mol Sci. 2020 Feb 21;21(4):1484. doi: 10.3390/ijms21041484.

182. Heller C, (Fenoglio C member of the GENFI). Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):263-270. doi: 10.1136/jnnp-2019-321954.

183. van der Lee SJet l (Fenoglio member of the EADB and IFGC groups). Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathol. 2020 May;139(5):959-962. doi: 10.1007/s00401-019-02107-8.

184. van der Ende EL et al., (Fenoglio member of the GENFI) . Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):612-621. doi: 10.1136/jnnp-2019-322493. Epub 2020 Apr 9.

185. Saresella M, Marventano I, Piancone F, La Rosa F, Galimberti D, Fenoglio C, Scarpini E, Clerici M.IL-33 and its decoy sST2 in patients with Alzheimer's disease and mild cognitive impairment. J Neuroinflammation. 2020 Jun 6;17(1):174. doi: 10.1186/s12974-020-01806-4.

186. Serpente M, Fenoglio C, D'Anca M, Arcaro M, Sorrentino F, Visconte C, Arighi A, Fumagalli GG, Porretti L, Cattaneo A, Ciani M, Zanardini R, Benussi L, Ghidoni R, Scarpini E, Galimberti D. MiRNA Profiling in Plasma Neural-Derived Small Extracellular Vesicles from Patients with Alzheimer's Disease. Cells. 2020 Jun 10;9(6):1443. doi: 10.3390/cells9061443.

187. Le Blanc G,(Fenoglio C member of the GENFI). Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Ann Neurol. 2020 Jul;88(1):113-122. doi: 10.1002/ana.25748. Epub 2020 May 12.

188. Gao Y, Wang T, Yu X et al (Fenoglio member of the IFGC group). Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Sci Rep. 2020 Jul 22;10(1):12184. doi: 10.1038/s41598-020-68848-9.

189. Tavares TP,(Fenoglio C. member of the GENFI). Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2020 Sep;91(9):975-984. doi: 10.1136/jnnp-2020-322987. Epub 2020 Aug 7.

190. Pietroboni AM, Carandini T, Dell'Arti L, Bovis F, Colombi A, De Riz MA, Casazza E, Scola E, Fenoglio C, Arighi A, Fumagalli GG, Triulzi F, Galimberti D, Viola F, Scarpini E. Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study. Neurol Sci. 2020 Nov;41(11):3175-3183. doi: 10.1007/s10072-020-04431-4. Epub 2020 Apr 30.

191. Convery RS, et al (Fenoglio C. member of the GENFI). Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in C9orf72 expansion carriers in the GENFI cohort. J Neurol Neurosurg Psychiatry. 2020 Dec;91(12):1325-1328. doi: 10.1136/jnnp-2020-323279

192. Scarioni M, Arighi A, Fenoglio C, Sorrentino F, Serpente M, Rotondo E, Mercurio M, Marotta G, Dijkstra AA, Pijnenburg YAL, Scarpini E, Galimberti D. Late-onset presentation and phenotypic heterogeneity of the rare R377W PSEN1 mutation. Eur J Neurol. 2020 Dec;27(12):2630-2634. doi: 10.1111/ene.14506. Epub 2020 Oct 12.

193. Russell LL, et al. (Fenoglio C member of the Genetic FTD Initiative, GENFI). Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex. 2020 Dec;133:384-398. doi: 10.1016/j.cortex.2020.08.023. Epub 2020 Sep 26.

194. van Waalwijk van Doorn LJC, Ghafoorian M, van Leijsen EMC, Claassen JAHR, Arighi A, Bozzali M, Cannas J, Cavedo E, Eusebi P, Farotti L, Fenoglio C, Fortea J, Frisoni GB, Galimberti D, Greco V, Herukka SK, Liu Y, Lleó A, de Mendonça A, Nobili FM, Parnetti L, Picco A, Pikkarainen M, Salvadori N, Scarpini E, Soininen H, Tarducci R, Urbani A, Vilaplana E, Meulenbroek O, Platel B, Verbeek MM, Kuiperij HB. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. J Alzheimers Dis. 2021;79(1):163-175. doi: 10.3233/JAD-200496.

195. Carandini T, Sacchi L, Ghezzi L, Pietroboni AM, Fenoglio C, Arighi A, Fumagalli GG, De Riz MA, Serpente M, Rotondo E, Scarpini E, Galimberti D. Detection of the SQSTM1 Mutation in a Patient with Early-Onset Hippocampal Amnestic Syndrome. J Alzheimers Dis. 2021;79(2):477-481. doi: 10.3233/JAD-201231.

196. Borrego-Écija S, et al. (Fenoglio C member of the Initiative GENFI). Disease-related cortical thinning in presymptomatic granulin mutation carriers. Neuroimage Clin. 2021;29:102540. doi: 10.1016/j.nicl.2020.102540.

197. Bocchetta M, et al. (Fenoglio C. member of the GENFI). Differential early subcortical involvement in genetic FTD within the GENFI cohort. Neuroimage Clin. 2021;30:102646. doi: 10.1016/j.nicl.2021.102646. Epub 2021 Mar 29.

198. Serpente M, Fenoglio C, Arighi A, Fumagalli GG, Arcaro M, Sorrentino F, Visconte C, Scarpini E, Galimberti D. Analysis of C9orf72 Intermediate Alleles in a Retrospective Cohort of Neurological Patients: Risk Factors for Alzheimer's Disease? J Alzheimers Dis. 2021;81(4):1445-1451. doi: 10.3233/JAD-210249.

199. Sorrentino F, Arighi A, Serpente M, Arosio B, Arcaro M, Visconte C, Rotondo E, Vimercati R, Ferri E, Fumagalli GG, Pietroboni AM, Carandini T, Scarpini E, Fenoglio C, Galimberti D. Niemann-Pick Type C 1 (NPC1) and NPC2 Gene Variability in Demented Patients with Evidence of Brain Amyloid Deposition. J Alzheimers Dis. 2021;83(3):1313-1323. doi: 10.3233/JAD-210453.

200. Benussi A, et al. (Fenoglio member of the GENFI). Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Netw Open. 2021 Jan 4;4(1):e2030194. doi: 10.1001/jamanetworkopen.2020.30194.

201. Tsvetanov KA, et al (Fenoglio C. member of the GENFI). Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimers Dement. 2021 Mar;17(3):500-514. doi: 10.1002/alz.12209.

202. Manera AL,(Fenoglio C. Member of GENFI Consortium). MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2021 Mar 15:jnnp-2020-324106. doi: 10.1136/jnnp-2020-324106. Online ahead of print.

203. Reus LM, Pasaniuc B, Posthuma D, Boltz T; International FTD-Genomics Consortium; Pijnenburg YAL, Ophoff RA. Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biol Psychiatry. 2021 Apr 15;89(8):825-835. doi: 10.1016/j.biopsych.2020.12.023. Epub 2021 Jan 9.

204 . Panman JL, Venkatraghavan V, van der Ende EL, Steketee RME, Jiskoot LC, Poos JM, Dopper EGP, Meeter LHH, Donker Kaat L, Rombouts SARB, Vernooij MW, Kievit AJA, Premi E, Cosseddu M, Bonomi E, Olives J, Rohrer JD, Sánchez-Valle R, Borroni B, Bron EE, Van Swieten JC, Papma JM, Klein S; GENFI consortium investigators. Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2021 May;92(5):494-501. doi: 10.1136/jnnp-2020-323541. Epub 2021 Jan 15.

205. Gallucci M, Mazzarolo AP, Focella L, Berlin E, Fiore V, Di Paola F, Bendini M, Zanusso G, Fenoglio C, Galimberti D, Bonanni L. More Atypical than Atypical Alzheimer's Disease Phenotypes: A Treviso Dementia (TREDEM) Registry Case Report. J Alzheimers Dis Rep. 2021 May 3;5(1):365-374. doi: 10.3233/ADR-210009.

206. Poos JM, et al., (Fenoglio C. member of GENFI). Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimers Dement (Amst). 2021 May 13;13(1):e12185. doi: 10.1002/dad2.12185. eCollection 2021.

207. Malpetti M, et al., (Fenoglio C. member of GENFI). Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimers Dement. 2021 Jun;17(6):969-983. doi: 10.1002/alz.12252. Epub 2020 Dec 14.

208. de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen IE, Pedersen NL, Stringa N, Zettergren A, Hernández I, Montrreal L, Antúnez C, Antonell A, Tankard RM, Bis JC, Sims R, Bellenguez C, Quintela I, González-Perez A, Calero M, Franco-Macías E, Macías J, Blesa R, Cervera-Carles L, Menéndez-González M, Frank-García A, Royo JL, Moreno F, Huerto Vilas R, Baquero M, Diez-Fairen M, Lage C, García-Madrona S, García-González P, Alarcón-Martín E, Valero S, Sotolongo-Grau O, Ullgren A, Naj AC, Lemstra AW, Benaque A, Pérez-Cordón A, Benussi A, Rábano A, Padovani A, Squassina A, de Mendonça A, Arias Pastor A, Kok AAL, Meggy A, Pastor AB, Espinosa A, Corma-Gómez A, Martín Montes A, Sanabria Á, DeStefano AL, Schneider A, Haapasalo A, Kinhult Ståhlbom A, Tybjærg-Hansen A, Hartmann AM, Spottke A, Corbatón-Anchuelo A, Rongve A, Borroni B, Arosio B, Nacmias B, Nordestgaard BG, Kunkle BW, Charbonnier C, Abdelnour C, Masullo C, Martínez Rodríguez C, Muñoz-Fernandez C, Dufouil C, Graff C, Ferreira CB, Chillotti C, Reynolds CA, Fenoglio C,et al. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nat Commun. 2021 Jun 7;12(1):3417. doi: 10.1038/s41467-021-22491-8.

209. D'Anca M, Fenoglio C, Buccellato FR, Visconte C, Galimberti D, Scarpini E. Extracellular Vesicles in Multiple Sclerosis: Role in the Pathogenesis and Potential Usefulness as Biomarkers and Therapeutic Tools. Cells. 2021 Jul 8;10(7):1733. doi: 10.3390/cells10071733.

210. Franklin HD, (Fenoglio C. member of GENFI). The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimers Res Ther. 2021 Jul 12;13(1):127. doi: 10.1186/s13195-021-00865-w.

211. Buccellato FR, D'Anca M, Fenoglio C, Scarpini E, Galimberti D. Role of Oxidative Damage in Alzheimer's Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery. Antioxidants (Basel). 2021 Aug 26;10(9):1353. doi: 10.3390/antiox10091353.

212. Young AL et al., (Fenoglio C. member of GENFI). Characterizing the Clinical Features and Atrophy Patterns of MAPT-Related Frontotemporal Dementia With Disease Progression Modeling. Neurology. 2021 Aug 31;97(9):e941-e952. doi: 10.1212/WNL.0000000000012410. Epub 2021 Jun 22.

213. La Rosa F, Mancuso R, Agostini S, Piancone F, Marventano I, Saresella M, Hernis A, Fenoglio C, Galimberti D, Scarpini E, Clerici M. Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer's Disease. Pharmaceuticals (Basel). 2021 Nov 20;14(11):1187. doi: 10.3390/ph14111187.

214. Bergström S, et al., (Fenoglio C. member of GENFI). A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Mol Neurodegener. 2021 Nov 27;16(1):79. doi: 10.1186/s13024-021-00499-4.

215. Wilke C, et al., (Fenoglio C. member of GENFI); Rohrer JD, Synofzik M. Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study. Ann Neurol. 2022 Jan;91(1):33-47. doi: 10.1002/ana.26265. Epub 2021 Nov 29.

216. Sacchi L, Carandini T, Fumagalli GG, Pietroboni AM, Contarino VE, Siggillino S, Arcaro M, Fenoglio C, et al. Unravelling the Association Between Amyloid-PET and Cerebrospinal Fluid Biomarkers in the

Alzheimer's Disease Spectrum: Who Really Deserves an A+? J Alzheimers Dis. 2022;85(3):1009-1020. doi: 10.3233/JAD-210593.

217. Premi E, et al., (Fenoglio C member of GENFI Consortium). An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. J Alzheimers Dis. 2022;86(1):205-218. doi: 10.3233/JAD-215447.

218. Poos JM, et al. (Fenoglio C. member of GENFI). Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimers Res Ther. 2022 Jan 19;14(1):10. doi: 10.1186/s13195-022-00958-0.

219. Peakman G, et al. (Fenoglio C. member of GENFI). Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. J Neurol Neurosurg Psychiatry. 2022 Feb;93(2):158-168. doi: 10.1136/jnnp-2021-326868. Epub 2021 Aug 5.

220. Pietroboni AM, Colombi A, Carandini T, Sacchi L, Fenoglio C, et al. Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage. Alzheimers Res Ther. 2022 Feb 12;14(1):33. doi: 10.1186/s13195-021-00933-1.

221. Öijerstedt L,et al. (Fenoglio C. member of GENFI). Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):336-339. doi: 10.1136/jnnp-2021-327005. Epub 2021 Aug 18.

222. Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, Naj AC, Campos-Martin R, Grenier-Boley B, Andrade V, Holmans PA, Boland A, Damotte V, van der Lee SJ, Costa MR, Kuulasmaa T, Yang Q, de Rojas I, Bis JC, Yaqub A, Prokic I, Chapuis J, Ahmad S, Giedraitis V, Aarsland D, Garcia-Gonzalez P, Abdelnour C, Alarcón-Martín E, Alcolea D, Alegret M, Alvarez I, Álvarez V, Armstrong NJ, Tsolaki A, Antúnez C, Appollonio I, Arcaro M, Archetti S, Pastor AA, Arosio B, Athanasiu L, Bailly H, Banaj N, Baquero M, Barral S, Beiser A, Pastor AB, Below JE, Benchek P, Benussi L, Berr C, Besse C, Bessi V, Binetti G, Bizarro A, Blesa R, Boada M, Boerwinkle E, Borroni B, Boschi S, Bossù P, Bråthen G, Bressler J, Bresner C, Brodaty H, Brookes KJ, Brusco LI, Buiza-Rueda D, Bûrger K, Burholt V, Bush WS, Calero M, Cantwell LB, Chene G, Chung J, Cuccaro ML, Carracedo Á, Cecchetti R, Cervera-Carles L, Charbonnier C, Chen HH, Chillotti C, Ciccone S, Claassen JAHR, Clark C, Conti E, Corma-Gómez A, Costantini E, Custodero C, Daian D, Dalmasso MC, Daniele A, Dardiotis E, Dartigues JF, de Deyn PP, de Paiva Lopes K, de Witte LD, Debette S, Deckert J, Del Ser T, Denning N, DeStefano A, Dichgans M, Diehl-Schmid J, Diez-Fairen M, Rossi PD, Djurovic S, Duron E, Düzel E, Dufouil C, Eiriksdottir G, Engelborghs S, Escott-Price V, Espinosa A, Ewers M, Faber KM, Fabrizio T, Nielsen SF, Fardo DW, Farotti L, Fenoglio C, et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet. 2022 Apr;54(4):412-436. doi: 10.1038/s41588-022-01024-z. Epub 2022 Apr 4.

223. D'Anca M, Buccellato FR, Fenoglio C, Galimberti D. Circular RNAs: Emblematic Players of Neurogenesis and Neurodegeneration. Int J Mol Sci. 2022 Apr 8;23(8):4134. doi: 10.3390/ijms23084134.

224. McCarthy J, et al. (Fenoglio C. member of GENFI). Data-driven staging of genetic frontotemporal dementia using multi-modal MRI. Hum Brain Mapp. 2022 Apr 15;43(6):1821-1835. doi: 10.1002/hbm.25727. Epub 2022 Feb 3.

225. Foster PH, et al., (Fenoglio C. member of GENFI). Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex. 2022 May;150:12-28. doi: 10.1016/j.cortex.2022.01.012. Epub 2022 Feb 9.

226. Nelson A, (Fenoglio C. member of GENFI). The CBI-R detects early behavioural impairment in genetic frontotemporal dementia. Ann Clin Transl Neurol. 2022 May;9(5):644-658. doi: 10.1002/acn3.51544. Epub 2022 Mar 26.

227. Scaroni F, Visconte C, Serpente M, Golia MT, Gabrielli M, Huiskamp M, Hulst HE, Carandini T, De Riz M, Pietroboni A, Rotondo E, Scarpini E, Galimberti D, Teunissen CE, van Dam M, de Jong BA, Fenoglio C, Verderio C. miR-150-5p and let-7b-5p in Blood Myeloid Extracellular Vesicles Track

Cognitive Symptoms in Patients with Multiple Sclerosis. Cells. 2022 May 5;11(9):1551. doi: 10.3390/cells11091551.

228. Gazzina S, et al. (Fenoglio C. member of GENFI). Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiol Aging. 2022 Jun;114:94-104. doi: 10.1016/j.neurobiolaging.2022.02.009. Epub 2022 Feb 26.

229. van der Ende EL, et al., (Fenoglio C member of GENFI consortium). A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain. 2022 Jun 3;145(5):1805-1817. doi: 10.1093/brain/awab382.

230. Benussi A, et al. (Fenoglio C. member of GENFI Consortium). Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimers Dement. 2022 Jul;18(7):1408-1423. doi: 10.1002/alz.12485. Epub 2021 Dec 7.

231. Wilson KM, et al., (Fenoglio C. member of Genetic FTD Initiative (GENFI). Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2022 Jul;93(7):761-771. doi: 10.1136/jnnp-2021-328710. Epub 2022 Apr 4.

232. La Rosa F, Zoia CP, Bazzini C, Bolognini A, Saresella M, Conti E, Ferrarese C, Piancone F, Marventano I, Galimberti D, Fenoglio C, Scarpini E, Clerici M. Modulation of MAPK- and PI3/AKT-Dependent Autophagy Signaling by Stavudine (D4T) in PBMC of Alzheimer's Disease Patients. Cells. 2022 Jul 12;11(14):2180. doi: 10.3390/cells11142180.

233. Bruffaerts R, et al. (Fenoglio C. member of GENFI). Hierarchical spectral clustering reveals brain size and shape changes in asymptomatic carriers of C9orf72. Brain Commun. 2022 Jul 18;4(4):fcac182. doi: 10.1093/braincomms/fcac182. eCollection 2022.

234. Poos JM,et al., (Fenoglio C. member of GENFI). Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology. 2022 Jul 19;99(3):e281-e295. doi: 10.1212/WNL.0000000000200384. Epub 2022 Apr 28.

235. Serpente M, Ghezzi L, Fenoglio C, Buccellato FR, Fumagalli GG, Rotondo E, Arcaro M, Arighi A, Galimberti D. miRNA Expression Is Increased in Serum from Patients with Semantic Variant Primary Progressive Aphasia. Int J Mol Sci. 2022 Jul 30;23(15):8487. doi: 10.3390/ijms23158487.

236. Bouzigues A, et al. (Fenoglio C. member of GENFI). Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. J Neurol. 2022 Aug;269(8):4322-4332. doi: 10.1007/s00415-022-11068-0. Epub 2022 Mar 29.

237. Sogorb-Esteve A,et al., (Fenoglio C. member of GENFI). Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia. Alzheimers Res Ther. 2022 Aug 31;14(1):118. doi: 10.1186/s13195-022-01042-3.

238. Koutsouleris N, Pantelis C, Velakoulis D, McGuire P, Dwyer DB, Urquijo-Castro MF, Paul R, Dong S, Popovic D, Oeztuerk O, Kambeitz J, Salokangas RKR, Hietala J, Bertolino A, Brambilla P, Upthegrove R, Wood SJ, Lencer R, Borgwardt S, Maj C, Nöthen M, Degenhardt F, Polyakova M, Mueller K, Villringer A, Danek A, Fassbender K, Fliessbach K, Jahn H, Kornhuber J, Landwehrmeyer B, Anderl-Straub S, Prudlo J, Synofzik M, Wiltfang J, Riedl L, Diehl-Schmid J, Otto M, Meisenzahl E, Falkai P, Schroeter ML; International FTD-Genetics Consortium (IFGC), the German Frontotemporal Lobar Degeneration (FTLD) Consortium, and the PRONIA Consortium. Exploring Links Between Psychosis and Frontotemporal Dementia Using Multimodal Machine Learning: Dementia Praecox Revisited. JAMA Psychiatry. 2022 Sep 1;79(9):907-919. doi: 10.1001/jamapsychiatry.2022.2075. PMID: 35921104; PMCID: PMC9350851.

239. van der Ende EL,et al. (Fenoglio C. member of GENFI). Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study. J Neuroinflammation. 2022 Sep 5;19(1):217. doi: 10.1186/s12974-022-02573-0. PMID: 36064709; PMCID: PMC9446850.

240. Arighi A, Arcaro M, Fumagalli GG, Carandini T, Pietroboni AM, Sacchi L, Fenoglio C, Serpente M, Sorrentino F, Isgrò G, Turkheimer F, Scarpini E, Galimberti D. Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation. Alzheimers Res Ther. 2022 Sep 17;14(1):135. doi: 10.1186/s13195-022-01077-6. PMID: 36115967; PMCID: PMC9482276.

241. Staffaroni AM, et al. (Fenoglio C. included in the Frontotemporal Dementia Prevention Initiative (FPI) Investigators). Temporal order of clinical and biomarker changes in familial frontotemporal dementia. Nat Med. 2022 Oct;28(10):2194-2206. doi: 10.1038/s41591-022-01942-9. Epub 2022 Sep 22. PMID: 36138153.

242. Arcaro M, Fenoglio C, et alA Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer's Disease. Biomedicines. 2022 Oct 21;10(10):2667. doi: 10.3390/biomedicines10102667. PMID: 36289929; PMCID: PMC9599653.

243. Woollacott IOC,et al., (Fenoglio C. member of GENFI). CSF glial markers are elevated in a subset of patients with genetic frontotemporal dementia. Ann Clin Transl Neurol. 2022 Nov;9(11):1764-1777. doi: 10.1002/acn3.51672. Epub 2022 Oct 17. PMID: 36245297; PMCID: PMC9639635.

244. Whiteside DJ,et al., (Fenoglio C. member of GENFI). Temporal dynamics predict symptom onset and cognitive decline in familial frontotemporal dementia. Alzheimers Dement. 2022 Nov 15. doi: 10.1002/alz.12824. Epub ahead of print. PMID: 36377606.

245. Samra K, et al (Fenoglio C. member of GENFI). Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales. J Neurol. 2022 Nov 17. doi: 10.1007/s00415-022-11442-y. Epub ahead of print. PMID: 36385202.

246. Fenoglio C, Serpente M, Visconte C, Arcaro M, Sorrentino F, D'Anca M, Arighi A, Rotondo E, Vimercati R, Rossi G, Scarpini E, Galimberti D. Circulating Non-Coding RNA Levels Are Altered in Autosomal Dominant Frontotemporal Dementia. Int J Mol Sci. 2022 Nov 25;23(23):14723. doi: 10.3390/ijms232314723. PMID: 36499048; PMCID: PMC9737170.

247. Pérez-Millan A,et al., (Fenoglio C. member of GENFI). Loss of brainstem white matter predicts onset and motor neuron symptoms in C9orf72 expansion carriers: a GENFI study. J Neurol. 2022 Nov 29. doi: 10.1007/s00415-022-11435-x. Epub ahead of print. PMID: 36443488.

248. Finger E, et al., (Fenoglio C. member of GENFI). Neurodevelopmental effects of genetic frontotemporal dementia in young adult mutation carriers. Brain. 2022 Dec 2:awac446. doi: 10.1093/brain/awac446. Epub ahead of print. PMID: 36458975.

249. Samra K,et al., (Fenoglio C. member of GENFI). Language impairment in the genetic forms of behavioural variant frontotemporal dementia. J Neurol. 2022 Dec 20. doi: 10.1007/s00415-022-11512-1. Epub ahead of print. PMID: 36538154.

250. Pietroboni AM, Colombi A, Contarino VE, Russo FML, Conte G, Morabito A, Siggillino S, Carandini T, Fenoglio C, et al. Quantitative susceptibility mapping of the normal-appearing white matter as a potential new marker of disability progression in multiple sclerosis. Eur Radiol. 2022 Dec 23. doi: 10.1007/s00330-022-09338-6. Epub ahead of print. PMID: 36562783.

251. Shafiei G,et al., (Fenoglio C. member of GENFI). Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. Brain. 2023 Jan 5;146(1):321-336. doi: 10.1093/brain/awac069. PMID: 35188955; PMCID: PMC9825569.

252. Samra K, et al., (Fenoglio C. member of GENFI). Neuropsychiatric symptoms in genetic frontotemporal dementia: developing a new module for Clinical Rating Scales. J Neurol Neurosurg Psychiatry. 2023 Jan 10:jnnp-2022-330152. doi: 10.1136/jnnp-2022-330152. Epub ahead of print. PMID: 36627201.

253. Meloni M, Agliardi C, Guerini FR, Zanzottera M, Bolognesi E, Picciolini S, Marano M, Magliozzi A, Di Fonzo A, Arighi A, Fenoglio C, Franco G, Arienti F, Saibene FL, Navarro J, Clerici M. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms.Neurobiol Dis. 2023 Jan;176:105947. doi: 10.1016/j.nbd.2022.105947. Epub 2022 Dec 5.

254. Visconte C, Golia MT, Fenoglio C, Serpente M, Gabrielli M, Arcaro M, Sorrentino F, Busnelli M, Arighi A, Fumagalli G, Rotondo E, Rossi P, Arosio B, Scarpini E, Verderio C, Galimberti D. Plasma microglial-derived extracellular vesicles are increased in frail patients with Mild Cognitive Impairment and exert a neurotoxic effect. Geroscience. 2023 Feb 1. doi: 10.1007/s11357-023-00746-0. Epub ahead of print. PMID: 36725819.

ALTRE INFORMAZIONI

2012: possesso di abilitazione scientifica nazionale alle funzioni di professore universitario di Seconda Fascia nei settori concorsuali : 06/A1 Genetica Medica, 05/F1 Biologia Applicata.

Revisore per le seguenti riviste scientifiche internazionali censite: Journal of Neuroinflammation, Journal of Alzheimer's Disease, Biological Psichiatry, International Journal of Molecular Sciences, Journal of Neurology, Journal of Neurology, Neurosurgery, and Psychiatry, European Journal of Neurology, Expert Opinion On Therapeutic Targets, Human Immunology, cells, IJMS.

Revisore di grant per: Alzheimer's Association, SAO-FRMA Fondation pour la recherché sur la maladie d'Azlheimer, Research Foundation Flanders (Fonds Wetenschappelijk Onderzoek - Vlaanderen, FWO, National Science Centre Poland, Multiple Sclerosis Research Australia. FISM-AISM Associazione Italiana Sclerosi multipla

Aprile 2007- Maggio 2007, Agosto 2008: periodi trascorsi presso il Dipartimento di Neurologia della Washington University di St. Louis (MO, USA) per lo svolgimento di un progetto di ricerca collaborativo sul ruolo di varianti genetiche delle molecole di adesione nella Sclerosi Multipla. Supervisors: Dott.ssa Laura Piccio, Dott.ssa A. Cross

2003 Attestato di abilitazione all'esercizio della professione di biologo.

H-index (Scopus): 47
ORCID: 000-0001-6332-4721

Data 08/02/2023 Luogo Milano